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ABSTRACT 
Inflammatory bowel diseases are associated with increased risk of developing colitis-
associated colorectal cancer (CAC). Epidemiological data show that the consumption of 
ω-3 polyunsaturated fatty acids (ω-3 PUFAs) decreases the risk of sporadic colorectal 
cancer (CRC). Importantly, recent data have shown that eicosapentaenoic acid-free fatty 
acid (EPA-FFA) reduces polyps formation and growth in models of familial 
adenomatous polyposis. However, the effects of dietary EPA-FFA are unknown in 
CAC. We tested the effectiveness of substituting EPA-FFA, for other dietary fats, in 
preventing inflammation and cancer in the AOM-DSS model of CAC. The AOM-DSS 
protocols were designed to evaluate the effect of EPA-FFA on both initiation and 
promotion of carcinogenesis. We found that EPA-FFA diet strongly decreased tumor 
multiplicity, incidence and maximum tumor size in the promotion and initiation arms. 
Moreover EPA-FFA, in particular in the initiation arm, led to reduced cell proliferation 
and nuclear β-catenin expression, whilst it increased apoptosis. In both arms, EPA-FFA 
treatment led to increased membrane switch from ω-6 to ω-3 PUFAs and a concomitant 
reduction in PGE2 production. We observed no significant changes in intestinal 
inflammation between EPA-FFA treated arms and AOM-DSS controls. Importantly, we 
found that EPA-FFA treatment restored the loss of Notch signaling found in the AOM-
DSS control, resulted in the enrichment of Lactobacillus species in the gut microbiota 
and led to tumor suppressor miR34-a induction. In conclusion, our data suggest that 
EPA-FFA is an effective chemopreventive agent in CAC. 
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1.INTRODUCTION 
1.1 Colorectal cancer 
Colorectal cancer (CRC) identifies a malignant transformation affecting the colon or the 
rectum, which are the first and the final sections of the large intestine, respectively. In 
most cases (~ 95%) colorectal cancer occurs as adenocarcinoma originated by glandular 
epithelium, while rare types of CRC include melanoma, sarcoma, carcinoid, squamous 
cell carcinoma or lymphoma (DiSario et al., 1994). Constituting the third most 
commonly diagnosed cancer in men and the second in females, CRC represents one of 
the major type of cancer worldwide (Jemal et al, 2011). In 2014 the estimated number 
of newly diagnosed CRC cases in the United States was 136.830, of which 50.310 dead 
(Siegel et al., 2014). Colorectal cancer incidence and death rate increase with the age. It 
has been estimated that approximately 90% of new cases were diagnosed in adults 50 
years old or older (Haggar and Boushey, 2009). Interestingly, there is a disparity in 
CRC incidence in relation to the geographical distribution characterized by the highest 
frequency in economically developed countries, in particular Australia/New Zealand, 
United States and Europe, respect to developing countries with a lower incidence in 
Africa and South-Central Asia (Figure 1). Indeed, the probability to develop CRC in the 
more developed areas results to be higher respect the less developed areas (Jemal et al., 
2011) This disparity in CRC incidence rates among the countries suggest the crucial 
role of lifestyle and environment as crucial risk factors in CRC development. Among 
the modifiable factors occurring in the promotion of CRC, the dietary habits, obesity, 
cigarette smoking and heavy alcohol consumption represent the main determinants 
(Huxley et al., 2009). However, although environmental factors play a critical role in 
the etiology of CRC, inheritance or genetic predisposition, as well as a bowel chronic 
inflammatory state also importantly contribute to the onset and progression of CRC. 
According to the disease background there are three main subsets of CRC: sporadic, 
hereditary or familial, and inflammatory-driven CRC.  
INTRODUCTION 
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Figure 1 Colorectal cancer incidence rates by sex and world area 
(Jemal et al, 2011.) 
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1.1.1 Sporadic colorectal cancer 
CRC is a heterogeneous disease which can occur sporadically in absence of a defined 
inherited and familial component or a predisposing disease, in the 75-80% of cases 
(Morán et al., 2010). The development of sporadic CRC evolves through a multistep 
process called 'adenoma-carcinoma sequence' in which a carcinoma develop from a 
preexisting benign adenoma through morphological changes accompanied by an 
accumulation of genetic and epigenetic alterations (Fearon and Vogelstein, 1990). 
Aberrant crypt foci (ACF) were identified as the early detectable dysplastic lesion in the 
colon (Siu et al., 1997) and defined as colonic crypts which appear microscopically 
elevated, with a circumscribed lumen and increased epithelial thickness (Alrawi et al., 
2006). Sustained by a protumorigenic microenvironment which promote the acquisition 
of additional mutations, only a small fraction of ACF, can evolve in adenoma and then 
to colorectal carcinoma (Alrawi et al., 2006).  
Three main pathways resulted primarily involved in the onset of CRC: chromosomal 
instability (CIN), microsatellite instability (MSI) and CpG islands methylator phenotype 
(CIMP). The traditional CIN pathway follows the model proposed in 1990 by Fearon 
and Vogelstein, which pioneeringly described the temporal sequence of specific genetic 
alterations in the context of the 'adenoma-carcinoma' sequence (Fearon and Vogelstein, 
1990) (Figure 2a). In this model inactivating mutations in Adenomatous polyposis coli 
(APC) gene or loss of chromosome 5q which include the APC gene are an early event 
in the initiation of CRC. The importance of APC gene in the pathogenesis of CRC is 
due to its fundamental role in the suppression of the Wnt signaling pathway (Cadigan 
and Liu, 2006). Different events including truncating mutations, deletions, loss of 
heterozygosity (LOH) or epigenetic silencing may cause the inactivation of APC 
impairing its binding with β-catenin. In this condition, β-catenin is able to escape from 
the degradation pathway with a subsequent nuclear accumulation and transcription of 
oncogenes such as CYCLIN-D1 and C-MYC (Cadigan and Liu, 2006). Mutations in 
APC are followed by mutations in the oncogene KRAS which generally occur in the 
intermediate adenoma stage (Fearon and Vogelstein, 1990). KRAS encode for a 
guanosine triphosphate/guanosine diphosphate binding protein whose aberrant 
activation led to constitutive signaling of the downstream Ras/Raf/Mek/Erk pathway 
which critically regulate cell proliferation, differentiation, invasion and apoptosis 
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(Smith et al., 2002), (Smith et al., 2010). In addition, in the advanced adenoma, LOH 
which affect SMAD2,SMAD4 and DCC genes characterize the CIN phenotype (Colussi 
et al., 2013). Mutations in p53 gene or deletions of chromosome 17p harboring this 
gene, constitute a later event occurring during the malignant transformation from 
adenoma to carcinoma in situ (Fearon and Vogelstein, 1990). As a consequence of 
chromosomal alteration CIN tumors were typically characterized by aneuploidy and the 
prevalent localization of these tumors is the left, or distal, side of the colon (Grady and 
Carethers, 2008). Although the model proposed by Fearon and Vogelstein has laid the 
foundation for the understanding of the molecular mechanisms underlying the 
development of sporadic CRC, subsequently it has been demonstrated that only 6.6% of 
CRC tumors was characterized by concurrent mutations in APC, KRAS and p53, while 
38% of tumors had mutations in only one of these three genes (Smith et al., 2002). 
Moreover, it was also found that more frequently (27.1%) there is a combination of 
APC and p53 mutations, whereas the occurrence of mutations in both p53 and KRAS 
genes is a rare event (Smith et al., 2002). These observations have led to consider the 
development of CRC in a more complex view. Indeed, alterations in additional 
pathways, as well as epigenetic changes in cancer related genes and modulation of non-
coding RNA importantly contribute to the malignant transformation (Pancione et al., 
2012). Shortly after the description of the CIN model of CRC, another model of genetic 
instability the so called ‘MSI pathway’ was introduced to explain the genetic alterations 
which occur during CRC development (Thibodeau et al., 1993) (Figure 2b). 
Microsatellites consist of repetitive units of 1-6 bases flanked by unique sequences, 
which are scattered around the genome (Thibodeau et al., 1993). The MSI phenotype 
arise from germline mutations in one or more of the genes encoding for components of 
the DNA mismatch repair (MMR) system (hMLH1, hMSH2, hMSH6, and hPMS2) 
(Thibodeau et al., 1993). Due to an improper recognition and elimination of mispaired 
base-pairs, defects in these genes are responsible for several insertions or deletions 
which affect microsatellites sequences within DNA (Ward et al., 2001). MSI account 
for approximately 15-20% of sporadic CRC and is the genetic cause of Lynch syndrome 
(Ward et al., 2001). CRCs characterized by the MSI phenotype frequently appear in the 
right colon and are generally diagnosed at a lower pathological state compared with 
CIN cancers (Pancione et al., 2012). Noteworthy, the MSI phenotype is associated with 
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a survival improvement and morphologically characterized by the presence of tumor 
infiltrating lymphocytes (Michael-Robinson et al., 2001). 
More recently, Toyota et al. proposed the term CIMP phenotype to define a different 
subset of CRCs which consistently show widespread CpG island hypermethylation, at 
seven different loci defined methylated in tumors (MINT) (Toyota et al., 1999). In this 
model, epigenetic events rather than changes in the DNA sequence, promote the 
development of CRC. Importantly, methylation at different MINT loci resulted 
significantly correlated with hMLH1 and CDKN2A (p16) methylation (Pancione et al., 
2012) Then, further loci appeared to be involved in the CIMP phenotype and the CIMP 
panel was expanded including: CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 
(Weisenberger et al., 2006). Importantly, Weisenberger and colleagues found that the 
CIMP phenotype frequently occur in presence of BRAF V600E mutations, while the 
relationship with KRAS mutations is uncertain (Weisenberger et al., 2006). An overlap 
between CIMP positive tumors and MSI-CRCs was also observed. In particular, 
hMLH1 methylation, which is the main mechanism of MMR genes silencing, frequently 
occur during CIMP tumorigenesis. CIMP CRCs have frequent proximal localization, 
often in the right colon, and are associated with the female sex and aging (Hawkins et 
al., 2002). Recent interesting evidences further revised the classical sequence of CRC 
development emphasizing the malignant potential of hyperplastic lesions which can 
evolve in a serrated polyp neoplasia and finally in an MSI-carcinoma (O’Brien et al., 
2006). In these tumors, BRAF is viewed as a 'gatekeeper' gene and its mutations are 
considered as a specific marker for the serrated polyp pathway. Importantly, the 
occurrence of the CIMP phenotype is an early event in this sequence, while MSI 
develops later (O’Brien et al., 2006) (Figure 2c). 
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Figure 2 Molecular pathways involved in CRC development 
(Ahnen, 2011) 
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1.1.2 Hereditary colorectal cancer  
Although most CRC occurs sporadically (approximately 95–99% of cases), a lower 
percentage of cases (2% to 5%) are hereditary or familial forms of this disease (Stoffel 
et al., 2014), (Jasperson et al., 2010). According to the absence or presence of polyposis, 
we can distinguish the hereditary forms of CRC in two main categories, Lynch 
syndrome (previously known as hereditary nonpolyposis colorectal cancer or HNPCC) 
and the polyposis syndromes, respectively. The latter can be further divided in subtypes 
including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), MUTYH-
associated polyposis (MAP) and other rare hereditary syndromes such as Peutz-Jeghers 
syndrome, Cowden syndrome and juvenile polyposis (Allen and Terdiman, 2003). All 
these syndromes were characterized by germ-line mutations which confer a major risk 
to develop CRC with an early age of onset respect to the sporadic forms (Burt and 
Neklason, 2005).  
1.1.2.1 Lynch Syndrome  
Lynch Syndrome (previously known as HNPCC), identifies an autosomal dominant 
disorder characterized by an early onset of colorectal cancer (approximately 44 years) 
which typically occur without polyposis, with a predilection for the right colon. Lynch 
syndrome is the most common form of hereditary CRC accounting for the 15% of all 
CRC (Umar et al., 2004). Patients with Lynch syndrome have an 80% lifetime risk to 
develop CRC (Umar et al., 2004). A distinctive feature of Lynch syndrome is the 
presence of extracolonic malignancies in addition to colorectal cancer, including 
endometrial, ovarian, gastric, pancreatic, small bowel, brain, hepatobiliary and 
urothelial neoplasms (Lynch and Lynch, 2000). Mutations in each of the mismatch-
repair (MMR) genes MLH1, MSH2, MSH6, and PMS2, can be responsible for this 
phenotype, although mutations in MLH1 and MSH2 gene occur more frequently 
accounting for the 90% of all MMR gene mutations (de la Chapelle, 2004). In a subset 
of cases, Lynch syndrome is due to 3' end deletion of the EPCAM gene, with 
subsequent epigenetic silencing of MSH2 (Sehgal et al., 2014). In most cases, patients 
inherited a germinal mutation in one copy of the MMR gene, while the inactivation of 
the remaining wild-type allele occur later and represents a somatic event. Given the 
INTRODUCTION 
17 
 
fundamental role of the MMR system to recognize and correct mispaired bases, as well 
as insertion/deletion events that may arise during DNA replication, mutations in these 
genes leads to an accumulation of replication errors in microsatellites sequences giving 
arise to an MSI phenotype, which is the hallmark of Lynch syndrome (de la Chapelle, 
2004).  
  
1.1.2.2 Familial Adenomatous Polyposis   
The FAP is as rare autosomal dominant disease with a penetrance close to 100%. The 
clinical phenotype of FAP, defined as the prototype of hereditary polyposis syndrome, 
is characterized by the presence of multiple (hundred to thousand) adenomatous polyps 
along the colon and the rectum. The age of onset is early and the symptoms generally 
occur during childhood or adolescence (Shussman and Wexner, 2014). Although the 
risk to develop CRC in FAP patients is near to 100%, it is estimated that less than 1% of 
all CRCs are due to FAP. This condition arises in presence of germline mutations in the 
tumor suppressor gene APC. The APC protein is a fundamental component of the 
scaffold complex implicated in the degradation of β-catenin and is a central negative 
regulator of Wnt signaling in the malignant transformation of colonic epithelial cells 
(Morin et al., 1997). Most mutations are nonsense or frameshift resulting in the 
synthesis of a truncated protein with subsequent accumulation of nuclear β-catenin and 
induced expression of tumor promoter genes (Chung, 2000), (Fearnhead, 2001). A 
distinct and less aggressive form of FAP is the AFAP, which is diagnosed when the 
number of colorectal adenomas ranges from ≥ 20 to ≤ 100. In this form adenomatous 
polyps occur later and there is a minor lifetime cancer risk respect to the classic FAP. 
The genetic basis of AFAP are less characterized and mutations in APC or MUTYH 
genes were found only in some cases (Knudsen et al., 2003).  
 
1.1.2.3 MUTYH-Associated Polyposis  
MAP, differently from FAP and other polyposis syndromes, is an autosomal recessive 
disease which appears in individuals with biallelic mutations in MUTYH gene, 
encoding for a DNA glycolase implicated in the Base Excision Repair system. In this 
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context, MUTYH is important to prevent DNA transversion (G:C to T:A) excising 
guanine mispaired with 2-hydroxyadenine and adenine opposite 8-oxoguanine (8-
oxoG), produced as effect of oxidative stress (Goodenberger and Lindor, 2011). In 
patients with MAP, a phenotype similar to AFAP was generally observed with the 
formation of ten to hundreds colorectal polyps in adulthood. A MAP syndrome is 
evaluated in patients with a suspected FAP missing mutations in APC gene or in 
absence of a family history (Morán et al., 2010). A 28-fold increase in CRC risk was 
found in carriers of biallelic mutations of MUTYH with a high predisposition for 
proximal disease. The risk appears to be age dependent and importantly increases in 
patients not subjected to regular endoscopic surveillance (Lubbe et al., 2009).  
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1.2 Colitis-associated Colorectal Cancer (CAC): an overview 
It is known that an inflammatory setting is an unfavourable condition predisposing and 
sustaining the development of a protumorigenic microenvironment which contribute to 
the onset of cancer (Mantovani et al., 2008). In this context, the inflammatory state  may 
be a preexisting condition that encourages the onset of a malignant process, or 
otherwise, oncogenic transformation can induce inflammatory mediators which 
contribute to create a tumor-promoting context. The effect of inflammation on sporadic 
CRC is essentially a promoting effect (Terzić et al., 2010). Differently, in Colitis-
associated colorectal cancer (CAC), a subtype of colorectal carcinoma occurring in 
patients with Inflammatory Bowel Disease (IBD), a chronic inflammatory disorder led 
to tumor formation acting both on initiation and promotion of CRC (Terzić et al., 2010). 
CAC represents one of the clearest evidence of the correlation between inflammation 
and cancer. The appearance of CRC as a consequence of IBD was first observed by 
Chron and Rosenberg in 1925 (Crohn and Rosenberg, 1925). Subsequently, this 
observation was strengthened and confirmed by several studies (Rubin et al., 2013)
, 
(Eaden et al., 2001) (Gyde et al., 1988). Although IBD-associated colorectal neoplasia 
account for only 1-2% of all CRCs, a preexisting condition of intestinal chronic 
inflammation constitute an important predisposing factor to develop CRC with a mean 
age of onset lower than sporadic CRC (40-50 years vs. 60 years) (Mattar et al., 2011). 
Both the main forms of IBD, Ulcerative colitis (UC) and Chron's disease (CD), confer 
an increased risk for developing CAC, in particular when inflammation extensively 
involve the colorectal tract (Ullman and Itzkowitz, 2011) (Farraye et al., 2010). 
However, while Ulcerative Colitis (UC) immediately appeared clearly involved in the 
pathogenesis of CAC, the existence of a consistent correlation with Chron's disease 
(CD) has been unclear for a long time (Waldner and Neurath, 2015). The difficulty to 
exactly estimate the risk of CRC in patients with CD is mainly due to the heterogeneity 
of the disease which can affect different parts of the gut (Waldner and Neurath, 2015). 
Different factors affect CAC incidence in IBD patients. In particular the duration and 
the severity of the disease, as well as the extent of colonic involvement are critical in 
CAC initiation (Rutter et al., 2004)
, 
(Ekbom et al., 1990). Indeed, the probability to 
develop CAC increases of 8% and 13% respectively after 20 and 30 years of the disease 
(Eaden et al., 2001). Although sporadic CRC and CAC share several molecular 
INTRODUCTION 
20 
 
mechanisms and both require accumulation of mutations for cancer development, 
important pathogenic differences discriminate these two types of CRC.  
1.2.1 Clinical and molecular features of CAC 
The development of CAC can  be clinically distinguished from sporadic CRC since they 
arise and evolve on a different genetic and clinical background. In sporadic CRC we 
observe the 'adenoma-carcinoma'  sequence previously described in which the 
malignant transformation begin from adenomatous polyps (Fearon and Vogelstein, 
1990). Differently, in CRC occurring in IBD patients we can recognize an 
'inflammation-dysplasia-carcinoma' sequence in which the tumor formation often derive 
from a flat and nonpolypoid dysplasia which frequently appears as a multifocal 
condition with the involvement of a larger area of the colon (Ullman and Itzkowitz, 
2011). The multifocality of CAC is thought to be due to the broad stimulus to which the 
colonic mucosa is subjected during a persistent inflammatory state (Xie and Itzkowitz, 
2008). For the assessment of epithelial dysplasia in IBD a standardized classification 
system is adopted which allow the identification of three main conditions: 1) the 
absence of dysplasia; 2) a state of indefinite dysplasia, with epithelial changes that 
exceed the limits of ordinary regeneration, but are not clearly classifiable as dysplastic 
areas or lesions; 3) a condition of positive dysplasia (Riddell et al., 1983). The positive 
dysplasia is further microscopically differentiated in low-grade dysplasia (LGD), in 
which the nuclei are still confined in the basal part of cells, and high-grade dysplasia 
(HGD) in which the nuclei are mainly localized in the apical region. This sequence of 
dysplastic conditions is generally observed in the evolution of CAC, although 
carcinoma can occur also skipping one of more of these steps (Farraye et al., 2010) 
(Figure 3). Regarding the molecular events that underlie and support the tumor 
formation, there is an overlap in the genomic alterations which are observed in sporadic 
CRC and CAC. For instance, the genomic instability in CIN and MSI, occurs 
approximately at the same rate in both types of CRC appearing with a frequency of 85% 
and 15%, respectively. Interestingly, the temporal sequence of genetic changes between 
sporadic CRC and CAC results opposite, showing important differences in their 
tumorigenic background (Ullman and Itzkowitz, 2011), (Xie and Itzkowitz, 2008). In 
sporadic CRC, mutations in APC gene are determinant constituting one of the first 
events responsible of the transition from normal mucosa to early adenoma. Otherwise, 
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the loss of APC function is usually a rare and a late event in IBD-associated neoplasia 
intervening in the shift from HGD to CAC (Ullman and Itzkowitz, 2011),
 
(Aust et al., 
2002). In addition, in sporadic CRC p53 inactivation is detected in the final steps of the 
multistage process, while in CAC, p53 alterations occur early and are sometimes 
observed in absence of dysplasia or in presence of indefinite dysplasia indicating that 
this event can be induced by a chronic inflammatory state preceding the onset of 
malignant transformation (Hussain et al., 2000a),
 
(Yin et al., 1993). Moreover, the loss 
of a p53 allele (p53 LOH) correlates with the evolution of dysplasia and it is found in 
85% of biopsies from UC patients histologically classified as carcinoma (Burmer et al., 
1992).  
 
 
Figure 3  Molecular pathogenesis of sporadic CRC and CAC 
(Ullman and Itzkowitz, 2011) 
 
Gene silencing by CpG island (CGI) hypermethylation represents another important 
molecular mechanism involved in sporadic CRC as well as in CAC setting, although 
this event results to be more frequent and relevant in the first case (Olaru et al., 2012). 
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An aging-related hypermethylation was observed in precancerous colonic lesions of 
patients with IBD, although the global CGI methylation pattern in CAC was also 
influenced by the CIMP status (Issa et al., 2001). In fact, standardization for age 
revealed a lower methylation rate in IBD patients with no CIMP phenotype respect to 
CAC occurring on CIMP positive
 
 background, the characteristics of which are similar 
to those of sporadic CRC (Olaru et al., 2012). In addition, hypermethylation of hMLH1 
promoter gene was detected in CAC characterized by a high-frequency MSI (MSI-H) 
inducing a defective DNA mismatch repair system (Fleisher et al., 2000). However, it is 
believed that alterations of DNA methylation are uncommon in CAC with a greater 
overall importance of genetic abnormalities than those epigenetic changes (Konishi et 
al., 2007).  
1.2.2 Mouse models of Colitis-associated colorectal cancer 
In order to understand the pathogenesis of cancer and to test new preventive as well as 
therapeutic options, the animal models are valuable tools to define the molecular 
mechanisms which underlie the onset of the disease in different settings. For the study 
of the hereditary forms of CRC different mouse models were generated. The Apc 
Min/+
 
mouse, which is created to have a truncating mutation in the APC gene, is a successfully 
used model for reproducing the clinical condition observed in patients with FAP 
(Yamada and Mori, 2007). Several other models which are based on the germinal 
inactivation or a conditional knock-out of APC were also developed (Nandan and Yang, 
2010). Mouse models hosting mutations in genes of the MMR system constitute the 
main strategy used for the study of Lynch syndrome (Nandan and Yang, 2010). To 
simulate the onset of sporadic CRC many chemicals pro-carcinogenic agents have been 
used including dimethyl hydrazine (DMH) and azoxymethane (AOM) whose efficiency 
in tumor induction strongly depends on the strain susceptibility, the dosage and the 
duration of the exposition (Karim and Huso, 2013). To best characterize the etiology 
and the behaviour of CAC, both genetic as well as chemical and pro-inflammatory 
protocols were developed, some of which will be discussed in detail.  
1.2.2.1 IL-10 -/- Mice Model 
IL-10 is an essential immunoregulatory and anti-inflammatory cytokine produced by 
regulatory T cells which plays a crucial role in the pathogenesis of IBD. Mice with 
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targeted deletion of IL-10 gene represents a genetically engineered mouse model which 
develop spontaneous colitis and colorectal cancer following the dysplastic sequence 
observed in patients with IBD-related CRC (Kühn et al., 1993). A massive production 
of pro-inflammatory mediators by macrophages and the induction of an important 
pathogenic Th1 response represents the main effects of IL-10 knock out (Berg et al., 
1996). Localized histopathologic signs of chronic colitis early appear in 3 weeks-old 
mutants mice, while multifocal dysplastic lesions appear in all regions of the large 
intestine in 3 months-old mutants associated with epithelial hyperplasia, crypt 
abscesses, inflammatory infiltrates in mucosa and submucosa (Berg et al., 1996). The 
adenocarcinoma incidence was of 25% at 3 months of age reaching the 60% at 6-
months of age (Berg et al., 1996). Importantly, although IL-10 KO develop colitis and 
CAC similarly to IBD patients, no alterations in p53, APC, K-RAS and MSH genes 
were found in this mouse model indicating the implication of additional mechanisms in 
the development of these cancers and placing a limit on the use of this animal model for 
the study of CAC (Sturlan et al., 2001).  
1.2.2.2 AOM-DSS Mouse model 
The azoxymethane-dextran sodium sulphate (AOM-DSS) model represents a chemical-
induced mouse model of CAC which rapidly recreate the inflammation-dysplasia-
carcinoma sequence occurring in patients with IBD-driven CRC. This model relies on 
the combined use of the pro-carcinogen (AOM) as tumor-inducing agent followed by 
repeated administrations of the proinflammatory agent (DSS). Irregularities and 
disorders of epithelial crypts, associated with inflammatory and immune infiltrating 
cells in the colonic mucosa, are early identifiable in this model with evident signs of 
extensive colonic inflammation detectable after 3-4 weeks of treatment (Neufert et al., 
2007),
 
(Tanaka et al., 2003). This two-stage colitis-related protocol led to a rapid 
development of multiple colonic tumors within 10 weeks, although the tumor incidence 
was different depending on the strain susceptibility. Indeed, the colonic adenocarcinoma 
incidence changes from 100% in Balb/c mice to 50% in C57BL/6N strain with no 
formation of colorectal adenocarcinomas observed in C3H/HeN mice and the DBA/2N 
mice (Suzuki et al., 2006). Moreover, the tumor-promoter activity of DSS in this model 
appeared to be dose-dependent in ICR mice reaching a 100% of tumor incidence in 
animals receiving AOM plus 2% of DSS (Suzuki et al., 2005). Colorectal 
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adenocarcinoma in AOM-DSS are mainly located in the distal or middle region of the 
colon and, interestingly, recapitulate crucial molecular alterations occurring in human 
colorectal cancer (Tanaka, 2012). Indeed, tumors in AOM-DSS model present 
alterations of the Wnt signaling pathway and are associated with a nuclear translocation 
of β-catenin, differently from IL-10−/− mice in which β-catenin localization is mainly 
membranous (Tanaka et al., 2003), (Gerling et al., 2011). However, despite the 
relevance of p53 alterations in CRC occurring on colitis background in humans, no 
mutations of p53 were generally found in AOM-DSS treated animals, while COX-2 and 
iNOS upregulation were commonly detected in the same murine model (Tanaka et al., 
2003). Therefore, given the great feasibility of the experimental protocol, as well as the 
high repeatability associated with reduced cost, AOM-DSS represents one of the models 
of choice when the study is focused on inflammatory-driven CRC. 
  
 
Figure 4 Representation of tumor progression in the AOM/DSS murine model  (De 
Robertis et al., 2011) 
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1.2.3 Oncogenic mechanisms in chronic inflammation  
In CAC, differently from sporadic CRC, tumor arises on a chronic inflammatory 
background which importantly contribute to the initiation of malignant transformation. 
Although the mechanisms which drive the onset of CAC in IBD patients need to be 
further defined, it is known that immune and inflammatory cells activated during colitis 
were able to produce reactive oxygen and nitrogen species and sustain a localized 
condition of oxidative stress which promote DNA damage (Terzić et al., 2010). The 
mutagen role of the oxidative stress in the pathogenesis of CAC was supported by 
Hussain and colleagues which demonstrated that the acquisition of p53 mutations in 
inflamed intestinal cells was related to an increased activity of iNOS (Hussain et al., 
2000). Enforcing this hypothesis, iNOS transcript levels resulted significantly 
upregulated at early stage of neoplasia development in the colonic mucosa of UC 
patients (Svec et al., 2010). There are also evidences that the ROS produced by 
inflammatory cells were able to inactivate members of MMR system at protein level as 
well as to induce an upregulation of DNA methyltransferase enzymes with a consequent 
epigenetic silencing of hMLH1 (Colotta et al., 2009). Moreover, the massive induction 
of proinflammatory cytokines and chemokines is a critical event for the neoplastic 
transformation which occur during the evolution from an IBD disease to the acquisition 
of a CAC phenotype. In addition, cytokines and chemokines are essential for sustaining 
carcinogenesis through the stimulation of cell proliferation and angiogenesis, as well as 
impairing the beneficial immune function (Terzić et al., 2010). The analysis of 
cytokines profile in the DSS mouse model of colitis performed at different times during 
the study, revealed that there are distinctive cytokine patterns in relation to the duration 
and the severity of the disease (Alex et al., 2009). In particular, during the transition 
from acute to chronic inflammation, a switch from Th1-Th17 derived cytokines to a 
prevalent Th2 inflammatory mediated response occur. According to these results, serum 
levels of TNF-α, IL-6, IFN-γ, IL-12, IL-17, MIP-1α and Keratinocyte-derived 
chemokine (KC) increased after 7 days of DSS administration, while during the chronic 
phase, IL-10 and IL-4 resulted upregulated at the expenses of TNF-α, IL-6, IL-17 and 
KC which resulted downregulated (Alex et al., 2009). Many cytokines were involved in 
the promotion of CAC, some of which seems to have a crucial role. The importance of 
the signaling mediated by TNF-α, a potent pro-inflammatory cytokine, in the onset of 
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CAC has been proven by several studies. In the AOM-DSS mouse model a significant 
lower number of tumors were observed in mice deficient in TNF-Rp55 gene (encoding 
for the receptor TNFR1 of TNF-α) compared with their WT AOM-DSS-treated 
counterpart (Popivanova et al., 2008). In addition, the treatment with the specific 
antagonist of TNF-α etanercept in AOM-DSS animals, showed less immune and 
inflammatory infiltrations and an important reduction of tumor numbers and size 
(Popivanova et al., 2008). Moreover, the activation of TNF-α receptor 2 (TNFR2) 
appeared to be critical in CAC development. (Onizawa et al., 2009). The beneficial 
effects of anti-TNF-α monoclonal antibodies were also proved in IBD patients, although 
the effect of TNF-α inhibition in humans with CAC remain to be defined (Waldner and 
Neurath, 2015). Another important cytokine implicated in the pathogenesis of CAC is 
IL-6. The inhibition of IL-6 signaling or IL-6 trans-signaling, respectively mediated by 
a membrane-bound IL6-receptor (IL6R) or by a soluble form of IL6R, led to a reduction 
of tumor development in AOM-DSS mouse model (Becker et al., 2004) The importance 
of IL-6 in the development of CAC was further confirmed by Matsumoto and 
colleagues which proved, using a colitis-associated premalignant cancer (CApC) model, 
the central role of both colonic and soluble IL-6 produced by colonic inflammatory 
macrophages in the induction of the transcription factor STAT3 and supported the 
anticancer effects arising through the inhibition of the IL-6 trans-signaling (Matsumoto 
et al., 2010). Also, Grivennikov and colleagues investigated the impact of IL-6 
deficiency in the AOM-DSS treated mice founding a decreased number, size and load 
of tumors in IL-6
-/- 
mice respect to their WT counterpart with a concordant reduction of 
colonic STAT3 expression (Grivennikov et al., 2009). Importantly, in the same study, 
the critical role of STAT3 hyperactivation for the evolution of CAC was enforced 
demonstrating a significant lower number and size of adenomas in mice with a 
conditional deletion of STAT3 (Stat3
ΔIEC
) (Grivennikov et al., 2009). Nuclear factor-
kappaB (NF-kB) is also thought to have an outstanding role in CAC. Different tumor 
promoter cytokines were able to activate the transcription factor NF-kB which in turn 
can mediate the synthesis of pro-inflammatory cytokines including TNF-α, IL-6, IL-8 
and IL-1β (Tak and Firestein, 2001). Greten and colleagues demonstrated that in the 
AOM-DSS mouse model the suppression of NF-kB activation, obtained through a 
conditional knockout of IKKβ in enterocytes, significantly reduced tumors number 
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while not affecting inflammation (Greten et al., 2004). In addition, they also 
encountered protective effects when IKKβ deficiency was induced in myeloid cells 
(lamina propria macrophages and dendritic cells) probably due to a downregulation of 
pro-inflammatory cytokines production which functions as growth factor for 
premalignant enterocytes (Greten et al., 2004)
, (Terzić et al., 2010). Moreover, a 
hyperactivation of NF-kB was found in macrophages and epithelial cells in the inflamed 
mucosa of patients with IBD compared to the normal colonic mucosa (Rogler et al., 
1998). However, opposite functions were proposed for NF-kB signaling during acute or 
chronic intestinal inflammation. Indeed, the inhibition of IKKβ-dependent NF-kB 
activation attenuate chronic intestinal inflammation, but exacerbate the acute phase of 
inflammation (Greten et al., 2004). The role of the transforming growth factor-β (TGF-
β) in CAC development appear to be dichotomic showing both promoting and 
suppressive effects. The tumor suppressive functions of TGF-β were supported by the 
evidence that mutations in TGF-β pathway including SMAD 3 and SMAD 4 in colonic 
epithelial cells promoted tumor development and progression in both sporadic and 
chronic colitis setting (Terzić et al., 2010). However, at later stage of carcinogenesis 
TGF-β showed a protumorigenic effect inducing an immunotolerant microenvironment 
and driving the epithelial mesenchimal transition (EMT) phenomenon leading to 
metastatic invasion (Terzić et al., 2010). 
MicroRNAs (miRNAs) represent an additional class of regulatory molecules 
importantly involved in the mechanisms linking inflammation to cancer (Iliopoulos, 
2014). miRNAs are small (18-24 nucleotides) non-coding, single-stranded RNA 
molecules which finely regulate gene expression at post-transcriptional level by 
targeting specific mRNAs for cleavage or translational repression (Bartel, 2004). 
Several miRNAs can be induced or downregulated upon inflammatory stimuli 
intervening in inflammation-associated carcinogenesis (Schetter et al., 2010). Oralu et 
al. evaluated the miRNA profiles in humans with IBD-associated neoplasia showing 22 
miRNAs significantly upregulated and 10 miRNAs significantly downregulated in 
inflamed-dysplastic tissues compared to non dysplastic inflamed mucosa (Olaru et al., 
2011). In particular, this study showed that miR-31 levels linearly increased with the 
malignant transformation which occur during CAC development (Olaru et al., 2011). 
Recently, a significant upregulation of miR-21,which is an IL-6 induced microRNA, 
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was detected in AOM-DSS mouse model supporting the oncogenic role of this 
microRNA in CAC (Gao et al., 2013), (Löffler et al., 2007). Differently, miR-143 and 
miR-145 have been proved to function as tumor suppressor in colon cancer and resulted 
significantly downregulated in patients with chronic UC, as well as in mice during DSS-
induced chronic inflammation (Pekow et al., 2012), (Josse et al., 2014)  
 
1.2.4 Intestinal microbiota and its role in CAC 
A complex symbiotic microbial community, including up to trillions of microorganisms 
(10
14
-10
15
) and more than 9 million of bacterial genes, widely exceeding the number of 
human cells and genes, is hosted in the human gastrointestinal tract, collectively 
constituting respectively the human gut microbiota and microbiome (Qin et al., 2010). 
There is a prevalence of strict anaerobic bacteria in the normal gut microbiota of the 
colon, and the two dominant bacterial phylogenetic divisions in the healthy adults are 
represented by Bacteroidetes and Firmicutes. Otherwise, relative minor proportion of 
Verrucomicrobia, Actinobacteria, Proteobacteria, Fusobacteria and Cyanobacteria phyla 
are recognized (Eckburg et al., 2005). However, while in terms of divisions healthy 
adults are less dissimilar, there is a great inter-individual variability in the relative 
proportion of these main components and these differences are more evident at lower 
taxonomic levels (Tap et al., 2009). There are strong evidences that our indigenous 
microbial community coevolves with us and that changes in the composition of the gut 
microbiota may have an important harmful or otherwise beneficial effect on human 
health (Qin et al., 2010). Indeed, the host physiology is critically modulated by these 
commensal bacteria defining the intestinal microbiota as an additional metabolic organ 
(Gill et al., 2006). Colonization  resistance against intestinal pathogens and invading 
microbes, as effect of a competition among bacterial genes, is one of the major function 
of the host-associated microbiota (Buffie and Pamer, 2013). This phenomenon, 
counteracting overgrowth of indigenous pathobionts and harmful pathogens, provide an 
important defense against microbial infection of the gut (Kamada et al., 2013). The gut 
microbiota appeared also to be fundamental for a proper development and 
differentiation of the intestinal epithelium as well as for the maintenance of a normal 
intestinal homeostasis and maturation and function of the host immune system (Sommer 
and Bäckhed, 2013). There is a growing number of evidences supporting a crucial role 
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of the intestinal microbiota in the onset of CAC. One of the assumption underlying the 
role of the gut microbiota in bowel related diseases concerns the establishment of an 
imbalance condition which is referred to as dysbiosis in which the healthy ratio between 
protective, and harmful (pro-inflammatory, protumorigenic or damage-inducing) 
bacterial strains results to be impaired (Tamboli et al., 2004), (Ullman and Itzkowitz, 
2011). In addition, it is known that microbial pathogens can induce intestinal 
inflammation promoting CAC development through the activation of pattern 
recognition receptors, toxins secretion as well as through the production of short chain 
fatty acids which are the main products of colonic fermentation (Terzić et al., 2010). 
Uronise and colleagues demonstrated that germ-free AOM-treated IL 10
-
/
- 
 mice 
appeared to be resistant to tumor development indicating  a tumor-promoting role of the 
intestinal bacteria (Uronis et al., 2009). In addition, the absence of the intestinal 
microflora, seems to confer resistance to tumor development in AOM-DSS mouse 
model of CAC, as well as the Apc Min/+  model of CRC (Li et al., 2012),(Zackular et 
al., 2013). There are also clear experimental evidences regard the existence of a 
colitogenic microbiota which is able to induce intestinal inflammation in normal mice. 
Importantly, the T-bet
−/−
RAG2
−/− 
ulcerative colitis (TRUC) animal model, showed that 
this colitogenic flora can be vertically transmitted to WT pups nursed from TURC mice 
and horizontally transmitted, as demonstrated by co-housing studies (Garrett et al., 
2007). The involvement of luminal bacteria in the pathogenesis of DSS-induced colitis 
was also proved by the amelioration of intestinal inflammation consequent to the 
treatment with selected antibiotics (Rath et al., 2001). However, other evidences 
highlighted a major susceptibility to DSS-induced colitis in germ-free mice and in mice 
treated with wide-spectrum antibiotics (Ayres et al., 2012). Interestingly, it has been 
recently demonstrated that, during the induction of CAC on AOM-DSS mouse model, 
important changes in the community structure of the gut occur, however not affecting 
the community membership indicating a variability in the relative abundance of the 
bacterial phylotypes rather than the appeareance of different phylotypes. Importantly, 
the authors of this study showed a correlation between the gut microbiota composition 
and the oncogenic  molecular events that flanked the development of CAC in its various 
phases over the time generating a longitudinal model which show the phylotype shifts 
as a complex and dynamic process (Liang et al., 2014).  
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Figure 5 Intestinal microbiota and cancer  
(Schwabe and Jobin, 2013) 
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1.3 The Notch signaling 
The Notch signalling pathway is an evolutionary conserved pathway which appears as a 
paradigmatic simple network, while intervening in a wide range of physiological and 
developmental cellular processes, as well as in different human diseases (Bray, 2006). 
Among the pleiotropic functions of Notch it is possible remark the regulation of cell 
fate determination in different cell types, the self-renewal of stem cells, as well as its 
implication in tumorigenesis through a modulation of important processes including cell 
death and proliferation (Andersson et al., 2011). Despite the functions mediated by this 
signalling can be extremely complex, most of the Notch-dependent processes were 
mediated by the same core pathway (Bray, 2006). In human and mice the core 
components of this pathway includes the five different Notch ligands (Jagged1, 
Jagged2, DLL1, DLL3 and DLL4) and four distinct Notch receptors (Notch1-4). Both 
Notch receptors and ligands are single-pass transmembrane proteins with extracellular 
domains characterized by multiple epidermal growth factor (EGF)-motifs which enable 
a cell-cell communication  which is essential to trigger the signaling mediated by the 
canonical Notch pathway (Rebay et al., 1991). Importantly, it has been demonstrated 
that of the 36 EGF repeats present on the extracellular portion of Notch receptors, only 
the repeats 11-12 of Notch are essential and sufficient to promote the physical 
interaction with both the specific ligands Delta and Jagged (Rebay et al., 1991). The 
Notch receptors are synthesized in a larger precursor form of 300 KDa which need to be 
further processed  in order to obtain a mature form. The first post-translational 
modification occur in the endoplasmic reticulum mediated by the enzyme O-
fucosyltransferase 1 (Ofut1) (Kopan and Ilagan, 2009). This enzyme works directly 
transferring fucose onto serine or threonine residues of EGF-like domains present on 
Notch receptors, a critical step to ensure the proper folding of the protein (Kopan and 
Ilagan, 2009). The furin-like convertase enzyme subsequently perform the cleavage of 
the glycosylated precursor in the trans-Golgi network generating respectively the N-
terminal extracellular domain of Notch (NECD) and the transmembrane-Notch 
intracellular domain named (NICD) which are non-covalently linked to form a 
heterodimer which constitute the mature receptor (Bray, 2006). This complex is further 
glycosylated during the passage through the Golgi by Fringe glycosyltransferase 
enzymes. In mammals three different fringe proteins were expressed: Lunatic Fringe 
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(LFng), Manic Fringe (MnFg) or Radical Fringe (RFng). There are evidences that all 
these fringe proteins were able to potentiate the signaling of Notch1 induced by Delta1 
enforcing the binding between the receptor and  its ligand. However, although none of 
these enzymes impaired the binding of Jagged1 to Notch1, the signalling deriving by 
this interaction appeared to be compromised by LFng and MnFg indicating the 
importance of this step in the modulation of Notch activity (Yang et al., 2005). Reached 
the mature form Notch receptors were translocated on cell surface where, upon binding 
with the specific ligand expressed on an opposing cell surface, the signaling is activated. 
The receptor-ligand binding triggers two consecutive proteolytic cleavages in the 
receptor. The first proteolityc event, catalyzed by the TACE metalloproteinase 
(ADAM17) cleaves the extracellular portion of the receptor (NECD) which was after 
internalized through endocytosis by the ligand-expressing cell for lysosomal 
degradation (Guruharsha et al., 2012). The remaining membrane-anchored fragment 
which derive from the first cleavage, is further processed by the γ-secretase enzyme 
releasing the active intracellular domain of Notch (NICD) (Kopan, 2012). In canonical 
Notch signaling, NICD translocate into the nucleus and interact with the transcriptional 
repressor protein CSL/RBP-J. Following the recruitment of co-activators Mastermind-
like (MAML) and the histone acetyltransferase (HAT) p300, CSL/RBP-J is converted to 
a transcriptional activator leading to the induction of downstream target genes including  
Hes1 and c-Myc (Figure 6) (Kopan, 2012). Importantly, over the years a non-canonical 
role for Notch signaling was reported which functions in a CSL/RBP-J-independent 
manner  and can be either ligand-dependent or independent(Andersen et al., 2012). An 
important effect of the non-canonical signaling is the regulation of the Wnt signaling 
pathway affecting the stability of β-catenin (Andersen et al., 2012). Noteworthy, 
representing an alternative crucial role of the Notch pathway,  the non-canonical 
activation of this signaling, occurring  with a ligand independent mechanism, resulted 
frequently associated with antagonism of Wnt/ β-catenin, a negative regulation evident 
also at the transcriptional level (Andersen et al., 2012). 
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Figure 6  The Notch signaling 
(Osborne and Minter, 2007) 
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1.3.1 Notch signaling in CRC 
In the normal intestine, Notch signaling is crucial for the maintenance of stem cell 
phenotype as well as for the regulation of cell fate determination (Miyamoto and 
Rosenberg, 2011). The implication of  Notch system in the development of CRC has 
been proved in several studies. In Apc 
Min/+
 mouse model of FAP it has been 
demonstrated that knocking down the  Notch transcription factor CSL/RBP-J or 
blocking the signaling with an inhibitor of γ-secretase, a massive conversion of crypt 
proliferative cells in post-mitotic goblet cells was induced indicating the critical role of 
the Notch activation in the definition of the colon crypt compartment and adenoma 
formation (van Es et al., 2005). The gene expression profile of HES1, a downstream 
target of Notch signaling, appeared to be constant, although variable in tumors of 
patients with sporadic or familial CRC, supporting the concept that Notch signaling is a 
consistent feature of human CRC (Reedijk et al., 2008). Sonoshita et al. recently 
reported that the knock-out of Aes (or Grg5), a negative regulator of Notch signaling, in 
Apc 
Min/+
 was associated with local tumor invasion and intravasion suggesting that 
Notch signaling inhibition could be a promising strategy for treatment of colon cancer 
metastasis (Sonoshita et al., 2011). Noteworthy, differently from other studies which 
reported an increased tumor formation in Apc 
Min/+
 
 
mice as effect of Notch signaling 
activation, in this  study the genetic depletion of Aes did not result in enhanced tumor 
formation and didn't affect cell proliferation in colon cancer cells or grafting 
experiments (Sonoshita et al., 2011). Although there are proof relative to an oncogenic 
role of the Notch signaling, conflicting evidences support a more complex framework 
for this pathway in the pathogenesis of CRC. Recently, Kim et al. showed that inducing 
the activation of Notch1 in Apc 
Min/+
 
 
mice a phenotype conversion from intestinal high-
grade adenoma into low-grade adenoma was observed suggesting a negative effect on 
CRC progression. This tumor suppressor function of Notch1 in CRC resulted directly 
linked to a downregulation of the Wnt/β-catenin pathway and importantly, in this study 
the Notch1 downstream target gene NRARP was proposed as reliable indicator of 
Notch1 activity in intestinal tumors (Kim et al., 2012a). The complex function of Notch 
signalling in CRC was further clarified by Garg et al. They previously demonstrated 
that MMP-9 functions as a protease able to cleaves and activates Notch1regulating 
goblet cell differentiation in colon (Garg et al., 2007). In a later study performed in 
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AOM-DSS mouse model of CAC they reported that activation of Notch1 downstream 
target p21
W
 
AF1/Cip1 
 was impaired in mice deficient for MMP-9 (MMP 9
 -/-
), while 
increased β-catenin was detected compared to the WT counterpart. Importantly, these 
events observed in MMP 9
 -/-
, resulted correlated with increased susceptibility to CAC 
(Garg et al., 2010). In addition, they tested in vitro the effects of MMP-9 overexpression 
showing an increased activation of Notch1 concomitant to a reciprocal downregulation 
of β-catenin (Garg et al., 2010). Concluding they proposed a tumor suppressor function 
of MMP-9 and Notch1 in CAC which occur through an intriguing interplay with the 
Wnt signalling in accordance with the results of Kim et al. previously discussed. 
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1.4 Polyunsaturated fatty acids 
Fatty acids (FAs) are carboxylic acids consisting of a long hydrocarbon chain with a 
carboxylic (-COOH) and a methyl group (-CH3) located at the two ends respectively 
According to the nomenclature system widely adopted, the last carbon of the 
hydrocarbon chain is identified as n or ω. In addition, depending on the presence and 
the number of double bonds in the chain, FAs can be distinguished in three main classes 
: saturated fatty acids (SFAs) which have exclusively single bonds saturated with 
hydrogens atoms, monounsaturated fatty acids (MUFAs) which present only one double 
bond along the chain, and polyunsaturated fatty acids (PUFAs) characterized by the 
presence of multiple double bonds not saturated with hydrogen atoms. Given the 
importance of PUFAs for human health, and given the inability of the organism to 
produce them, they are classified as essential fatty acids, so they need to be introduced 
with the diet (Kaur et al., 2014). On the basis of the position of the first double bond in 
the chain starting from the methyl group we can discriminate ω-3 and ω-6 PUFAs as 
two main families of essential PUFAs (Wall et al., 2010). The main sources of Linoleic 
acid (LA; C18:2 ω-6), the precursor of ω-6 series fatty acids, are vegetable oils 
including corn, safflower and soybean oil, but a high content of LA is also found in nuts 
and sunflower seeds. Differently, ω-3 series fatty acids derive from α-linoleic acid 
(ALA; C18:3 ω-3) which can be introduced with the diet feeding fish oil, flaxseeds, 
rapeseeds, hempseed, canola oil (Das, 2006) The two essential short chain PUFAs, LA 
and ALA, were in vivo elongated and further unsaturated to long chain (LC) PUFAs in 
the endoplasmic reticulum through a biosynthetic pathway involving the Δ6- and Δ5-
desaturase enzyme and the elongase enzyme (Elovl-5 and Elovl-2). A β-oxidation 
reaction for fatty acid shortening finally occur in the peroxisomes (Emery et al., 2013). 
From the metabolism of LA mediated by these enzymes derive arachidonic acid (AA 
20:4 ω-6), while the ω-3 LC-PUFAs eicosapentaenoic acid (EPA 20:5 ω-3) and 
docosahexaenoic acid (DHA 22:6 ω-3) are the product of ALA conversion (Figure 6). 
The ability to convert PUFA in LC-PUFA among the species is not constant, but there 
is a variability in relation to the presence, the abundance and the activity of the enzymes 
involved in the metabolic pathway. In particular the activity of desaturase enzymes is 
known to be lower in humans compared to other species and is negatively regulated by 
multiple factors such as cholesterol, saturated fat and aging (Das, 2006). It is important 
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to underlie that the two main classes of LC-PUFAs described are not interconvertible 
and present distinct and often opposite physiological functions. There is a competition 
for accessing the Δ6-desaturase and the fatty acid elongase by ω-6 and ω-3 PUFAs for 
the bioconversion into LC-PUFA. In presence of both substrate the affinity of Δ6-
desaturase for ALA is higher than AA (Rodriguez et al., 1998). However, since LA 
constitute the most common source of PUFA introduced with the diet, in particular in 
the Western diet lifestyle, accounting for approximately 90% of dietary ω-6 intake, it 
represents the more frequent substrate of Δ6-desaturase enzyme (Harris et al., 2009). 
Hence, in order to reduce the synthesis of AA and the production of eicosanoids derived 
from ω-6 PUFAs metabolism, the dietary intake of ω-3 PUFAs should be implemented 
eating foods containing a high content of EPA and DHA, in particular oily fish such as 
salmon, mackerel and sardines (Hull, 2011).  
 
 
Figure 7  The ω-6 and ω-3 PUFAs metabolism 
(Das, 2010)
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1.4.1 Eicosanoids biosynthesis from PUFAs 
Once ingested and absorbed PUFAs were incorporated as lipid component into the 
phospholipids of many cellular membranes influencing their physical and chemical 
,properties as well as their function (Serhan and Chiang, 2008),
 
(Mitchell et al., 2003). 
The composition of lipidic microdomains including lipid rafts and caveolae also 
resulted to be modified after PUFA incorporation (Stillwell et al.). Given the inability of 
the body to synthesize ω-3 and ω-6 PUFAs de novo, their content into the cellular 
membranes is not constant, but highly determined by their dietary intake. The 
biologically activities of these compounds extends well beyond the influence on the 
membrane properties, but also intervening in the productions of bioactive lipids, named 
eicosanoids, which have pleiotropic and a complex function over the body (Larsson et 
al., 2004). The biosynthesis of eicosanoids occur upon activation of phospholipase A2 
(PLA2) enzyme resulting in LC-PUFA esterification, cleavage and release from 
phospholipids membrane. Subsequently, the 20-carbon PUFAs, including AA and EPA 
were further used as precursor for the eicosanoids synthesis which are bioactive 
hormon-like lipids with a short life, but a potent impact on many pathophysiological 
processes including the modulation of inflammatory and immune response, the 
regulation of cellular growth and differentiation, as well as platelet aggregation 
(Larsson et al., 2004). The eicosanoids biosynthesis is mediated by three main classes of 
enzymes which use both AA and EPA as substrates: the constitutive and inducible 
cyclooxygenases enzymes, respectively represented by COX-1 and COX-2 enzymes, 
the lipoxygenases (LOX) enzymes and cytochrome P450 monooxygenases (CYP). 
From the activity of COX enzymes derive the production of prostaglandins (PGs) and 
thromboxanes (TXs), while the LOX enzymes give rise to lipoxins (LXs), leukotrienes 
(LTs) and hydroxy fatty acids. At last hydroxy fatty acids, dihydroxy fatty acids, and 
epoxy fatty acids are the products generated from CYP enzyme (Larsson et al., 2004). 
Although AA and EPA uses the same enzymes for eicosanoids production, the families 
of eicosanoids produced from the different LC-PUFA is dissimilar. From the 
metabolism of AA were generated the 2-series PGs and TXs, the 4-series LTs and the 
hydroxy and hydroperoxy derivatives (5-HETE and 5-HPETE). Differently, when EPA 
is used as a substrate for COX and LOX enzymes, occur the production of the 3-series 
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PGs and TXs and the 5-series LTs (Lands, 1992). In addition, new classes of potent 
bioactive eicosanoids derived from both EPA and DHA metabolism have been recently 
identified including E- and D-series resolvins (RvE1, RvE2, RvD1, RvD2) protectins 
and docosatriens with important protective and anti-inflammatory properties (Serhan 
and Chiang, 2008) (Figure 6)  
1.4.2 Omega-3 PUFAs intake and CRC development  
The existence of a correlation between the dietary intake of PUFAs and the risk to 
develop CRC emerged from preliminary epidemiological data which reported a lower 
rate of CRC incidence in countries with a dietary lifestyle characterized by an increased 
fish consumption including Greenland and other Northeast countries respect to the 
Western populations (Byers, 1996). However, over the time epidemiological and 
observational human data appeared to be inconsistent regard this hypothesis reporting 
conflicting data probably as effect of heterogeneity of the studies, the difficulty to 
obtain appropriate values of  ω-3 and ω-6 PUFA dietary intake as well as other 
confounding elements (Cockbain et al., 2012a),
 
(Hull, 2011). Despite the inconsistency 
of the epidemiological evaluations, the anticancer effects of ω-3 PUFAs on CRC onset 
were importantly revealed by animal studies and begins to be also confirmed in 
different phases of clinical trials. Although there are experimental evidences of 
beneficial effects from a combination of both EPA and DHA intake (Cockbain et al., 
2012), we focused our attention on studies describing the effect of EPA alone. One of 
the first evidences become from rats treated with the carcinogen AOM to induce CRC 
in which the tumor incidence and multiplicity resulted significantly decreased in the 
group feeding a diet containing EPA 4.7% compared to the arm fed with linoleic acid 
diet (Minoura et al., 1988). These evidences were subsequently confirmed and enforced 
in Apc 
Min/+
 mouse model of FAP which develop multiple intestinal tumors at 5 weeks 
of age. In this study, Barone and colleagues observed a reduction of tumors number and 
size in mice feeding a salmon oil-enriched diet characterized by a high percentage of ω-
3 PUFAs compared with animals feeding a standard diet (Barone et al., 2014). In the 
same mouse model, our research group previously demonstrated that diets containing a 
different percentage (2.5% or 5%) of free-fatty acid (FFA) formulation of EPA are 
highly protective in CRC development compared to the control diets in which the corn 
oil, which is ω-6-PUFAs predominant, was substituted for soybean oil that contains 
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both ω-3- and ω-6-PUFA. They observe that the number of and load of tumors was 
dramatically decreased (over 70% and 80% respectively) in the animals feeding both 
EPA-FFA diets with a stronger effect of that containing 5% of EPA-FFA (Fini et al., 
2010). The efficacy of EPA-FFA observed in Apc 
Min/+
 mouse model led to a Phase III 
clinical trial in 55 patients with FAP which showed a significant lower number  and size 
of rectal polyps (22.4% and 29.8% respectively) in the group feeding EPA-FFA 2 g 
daily for 6 months compared to the placebo group (West et al., 2010). Similar results 
were obtained on patients with a familial history of colorectal adenomas feeding EPA-
FFA (2 g/day) for 3 months in which a significant reduction of crypt cell proliferation 
associated with an increased apoptosis rate was observed (Courtney et al., 2007). 
Noteworthy, it has been also demonstrated that these effects are directly attributable to 
the increased uptake of ω-3 PUFA and not only due to the reduction of the ω-6 PUFA 
content (Davidson et al., 2004). Importantly, since ω-3 PUFA are natural compounds, 
they appear to be safe and well tolerated, so they could represent efficient 
chemopreventive agents against CRC. 
 
1.4.3 Anti-neoplastic properties of omega-3 PUFAs on CRC 
The anti-neoplastic properties of ω-3 PUFAs can be recognized in different molecular 
and cellular mechanisms, many of which were characterized through in vitro studies. 
One of the proposed anticancer activity of ω-3 PUFAs is the inhibition of COX-2 
activity, the inducible form of COX enzymes, which is detected in many inflammatory 
processes, as well as in different types of cancer including CRC (Calviello et al., 2007). 
This effect is due to the ability of EPA to function as alternative substrate for COX-2 
enzymes stimulating the synthesis of anti-inflammatory and anti-tumorigenic '3-series' 
PGs (PGE-3) rather than the pro-tumorigenic and pro-inflammatory '2 series' PGs 
(PGE-2). A reduction of COX-2-driven PGE2 synthesis leading to a "PGE2-to-PGE3 
switch" was detected treating CRC cell lines with the ω-3 PUFA EPA in the FFA form 
(Hawcroft et al., 2010) In the same study, it has been also demonstrated that in presence 
of PGE-2, PGE-3 were able to antagonize the protumorigenic signaling mediated by the 
EP4 receptor (Hawcroft et al., 2010). In fat-1 transgenic mice, which convert 
endogenous ω-6 to ω-3 PUFAs, treated with AOM-DSS to induce CAC, a significant 
increase of PGE-3 production was appreciated at the expenses of ω-6 derived 
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eicosanoids including PGE-2 compared with the WT counterpart (Jia et al., 2008). Also 
the DHA appeared to be an alternative substrate for COX-2 enzyme and both EPA and 
DHA significantly decreased PGE-2 synthesis and tumor growth in nude mice 
inoculated with HT29 cells (Vecchio et al., 2010)
, 
(Calviello et al., 2004). The 
modulation of eicosanoids synthesis observed in presence of ω-3 PUFAs does not affect 
exclusively the PGs production, but also the induction of other lipid mediators as 
resolvins and protectins. Indeed, from the metabolism of EPA derive a COX-2 
dependent production of RvE1, while D-series resolvins and protectins are generated 
from DHA. These downstream effectors of both EPA and DHA showed important anti-
inflammatory and pro-resolution properties in animal models of acute inflammation 
contributing to explain the beneficial effects of these natural compounds (Serhan et al., 
2008). The pleiotropic effects of ω-3 PUFAs also occur through an alteration of the 
membrane organization. In particular, it is known the ability of ω-3 PUFAs to change 
the composition, structure and function of lipid rafts or caveolae. These lipids 
microdomains, enriched in cholesterol, sphingolipids and saturated acyl chains, 
compartmentalize proteins and lipids with specific function acting as dynamic signaling 
platforms. Therefore, their modulation could have an important meaning for the anti-
cancer activity of ω-3 PUFAs (Turk and Chapkin, 2013). For instance in splenic T cells 
of fat-1 mice larger rafts domains were observed compared to WT mice (Kim et al., 
2008). Moreover, it has been demonstrated an alteration of caveolae microenvironment 
in mouse colonic mucosa feeding ω-3 PUFAs which led to a significant reduction of 
cholesterol content, as well as of caveolin-1. In addition, also the distribution of 
caveolae signaling proteins such as H-RAS and eNOS resulted strongly modulated by 
ω-3 PUFAs (Ma et al., 2004). Importantly, ω-3 PUFAs not only modulate the size and 
the composition of lipid rafts, but also affect the localization of cell surface receptors 
such as the epidermal growth factor receptor (EGFR), which is a key receptor in colonic 
transformation. A displacement of EGFR was found in Young adult mouse colonic 
(YAMC) cells treated with DHA with a consequent impairment of transduction signal 
which is reflected in a modulation of cell proliferation. These results were also 
confirmed in vivo in which the suppression of EGFR signaling induced by DHA was 
also associated with a reduction of tumor incidence in AOM-DSS mouse model. This 
effect appear to be exclusively due to DHA since no variations in EGFR 
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phosphorylation were found in YAMC cells treated with EPA or AA (Turk et al., 2012). 
Although not direct effects of EPA in the modulation of EGFR signaling were reported, 
it is known that the migration and invasion induced by PGE-2 are dependent on EGFR 
transactivation indicating that EPA may be a similar functional effect of DHA impairing 
the PGE-2 synthesis (Hull, 2011),(Buchanan et al., 2003). There are also evidences of 
an anti-tumorigenic effect of ω-3 PUFAs due to an alteration of cellular redox state. 
Indeed, LC-PUFAs, as effect of their insaturation degree, appear to be particularly 
prone to lipid peroxidation. So, their incorporation in the cellular membrane can 
stimulate the generation of reactive oxygen species (ROS) and the establishment of a 
condition of oxidative stress. An enhancement of oxidative stress induced by the 
fermentation product butyrate was observed in mouse colonocytes treated with DHA 
which appear to be concomitant with an induction of apoptotic pathways (Ng et al., 
2005). In addition, it has been demonstrated that arsenic trioxide (As2O3) used in 
combination with DHA have strong, but selective cytotoxic effects on 7 solid tumor cell 
lines including SW620, HT-29 and LS147T CRC cell lines. Indeed, they didn't found 
toxic effects on cell deriving from healthy donor such as skin fibroblast, pheripheral 
blood mononuclear cells and microvascular endothelial cells. Interestingly, this effect 
on cell viability resulted associated with an increase of intracellular lipid peroxidation 
and induction of apoptosis (Baumgartner et al., 2004). Although a similar effect of 
oxidized ω-PUFAs could be hopeful, both beneficial and harmful effects were described 
for lipid peroxidation in cancer development. The protective effects of ω-3 PUFAs in 
cancer appeared to be also linked to the ability of these fatty acids to modulate gene 
expression though the activation of the peroxisome proliferator-activated receptors 
(PPARs). This nuclear receptor family includes three isoforms of PPAR, named α,β/δ, 
and γ which all heterodimerize with retinoid X receptor α (RXRα) (Lemberger et al., 
1996). Both PPAR γ and δ were expression in the colon and EPA and DHA constitute 
natural ligands for these receptors. In this context, the anti-neoplastic activity of omega-
3 could be related to the inhibition of cell proliferation and induction of apoptotic 
processes through a mechanism which is dependent of PPAR γ activation (Edwards and 
O’Flaherty, 2008).  
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2. AIM OF THE WORK  
Recently, our research group successfully tested the chemopreventive properties of a 
highly purified (99%) formulation of EPA supplied as the free fatty acid (EPA-FFA) in 
Apc 
Min
/
+ 
mouse model of FAP supporting an important tumor suppressor role of this 
bioactive compound (Fini et al., 2010) . In addition, EPA-FFA, has been demonstrated 
to reduce adenoma number and size in patients with familial adenomatous polyposis in 
a subsequent clinical trial conducted by another research group (West et al., 2010). 
However, the effect of dietary EPA-FFA on the onset of CAC remains to be elucidated. 
On the basis of these knowledge, this thesis investigates the potential chemopreventive 
effect of highly pure EPA-FFA on colitis-associated colorectal tumorigenesis with the 
following specific aims:  
 
 To evaluate the impact of  highly pure EPA-FFA dietary supplementation  on the 
initiation and promotion of colorectal tumors in AOM-DSS mouse model of 
CAC  
 
 To assess the effects of EPA-FFA dietary intake on colonic fatty acid 
composition and inflammation 
 
 To best characterize the molecular mechanisms affected by EPA-FFA on 
inflammation-driven CRC and to identify new molecular pathways targeted by 
EPA-FFA  
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3.MATERIALS & METHODS 
3.1 Animals 
3.1.1 Mice 
Five-week-old male C57BL/6J mice were obtained from Harlan Laboratories (San 
Pietro al Natisone, Udine, Italy) and housed in a temperature and humidity controlled 
animal facility with 12 hour light/dark cycle. All animal procedures were performed 
according to the animal protocol approved by the Institutional Animal Care committee 
of  the University of Naples Federico II (Naples Italy).  
3.1.2 Establishment of the Colitis-associated Cancer model 
In order to obtain a mouse model of colitis-associated colorectal cancer (CAC) sixty 
mice were subjected to a well-defined chemically inflammation based colorectal cancer 
protocol (Tanaka et al., 2003), (Neufert et al., 2007). This model combines the use of 
the chemical genotoxic agent azoxymethane (AOM) with the pro-inflammatory agent 
DSS resulting in a pro-carcinogenic setting which promote the experimental onset of 
inflammation-driven CRC. In this study sixty mice were intraperitoneally injected with 
a single dose of AOM 7.5 mg/Kg (Sigma-Aldrich, Milan, Italy) diluted in phosphate 
buffered saline (PBS) followed by three cycles of 2.5% Dextrane sulfate sodium (DSS) 
in drinking water (Microtech, Naples, Italy) each consisting of four days. Each DSS 
cycle was followed by 16 days of regular drinking water (Figure 8). 
3.1.3 Feeding protocol  
At the beginning of the study the animals were randomized in three arms (20 mice each) 
to be fed either the control diet (Control) or diet enriched with Eicosapentaenoic acid 
free fatty acid  (EPA-FFA) (ALFA, SLA Pharma AG, Switzerland). As Control diet the 
AIN-76A diet (Charles River Laboratory, Lecco, Italy) was used. EPA-FFA diets were 
obtained on the basis of the Control diet substituting 1% of the corn oil, which is ω-6 
predominant, with 1% of a highly purified (99%) formulation of EPA-FFA. On the 
basis of  previous experience (Fini et al., 2010), EPA-FFA stability was preserved 
enriching the food with antioxidant vitamins, sealing it and nitrogen flushed in foil bags. 
The diets were stored at 4°C and used within 3 days after opening. Being a protocol 
based on the diet, in order to minimize the variability among the arms, a fixed equal 
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amount of food was provided daily. Mice had free access to drink tap water. For the 
initiation protocol EPA-FFA diet was started four weeks before the AOM injection, 
while for the promotion protocol, which was designed in order to recreate the clinical 
scenario of patients with long-standing inflammatory bowel diseases, EPA-FFA diet 
was started after the first DSS cycle (Figure 7). Since it has been reported an 
exacerbation of DSS-induced colitis with a high rate of mortality and morbidity in 
presence of fish oil supplementation, during DSS cycles EPA-FFA diets were switched 
on Control diet. Eight C57BL/6J male mice were fed the Control diet without any 
additional treatment to be used as reference for some experiments (Healthy mice). Food 
intake was tracked daily and body weight was tracked three times per week. Rectal 
bleeding and diarrhea were also monitored during the study.  
3.1.4 Sacrifice of mice and colon harvesting  
Mice were euthanized after 15 weeks from the beginning of the protocol. Blood was 
collected by intracardiac puncture, serum samples were obtained after centrifugation at 
2.500 r.p.m at 4°C and stored at -80°C. Urine was taken through bladder aspiration and 
immediately stored at -80°C. Stools were also collected and stored at -80°C. During the 
sacrifice the colon from each mice was removed immediately, opened longitudinally 
and washed with cold PBS. At the sacrifice tumors macroscopically analysis was 
performed in blind evaluating the number and the location of visible tumors. Tumors 
size measurements were carried out using a digital caliper evaluating the largest and the 
perpendicular diameter. Fresh tissue samples from colon tumors and normal mucosa 
were collected and stored at -80°C. Given the low number of tumors encountered in 
EPA-FFA treated groups compared to the Control arm, all the molecular analysis were 
performed on adjacent normal mucosa in order to have homogeneity among  groups. 
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Figure 8 Experimental protocol of tumor induction and feeding in C57BL/6J mice.  After 
the AOM injection, animals were subjected to three cycles of DSS. The Control arm fed a 
Control (Control) diet for the entire duration of the protocol. The Initiation arm started 1% 
EPA-FFA diet 4 weeks before AOM, while for the promotion protocol EPA-FFA was started 
during the recovery after the first DSS cycle. EPA-FFA diet was switched on Control diet 
during each DSS cycle.  
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3.2 Histological analysis for colon  
3.2.1 Sample preparation 
For histological analysis colon tissues were fixed in 10% formalin (DIAPATH srl, 
Martinengo (BG), Italy)  solution at RT overnight. The samples were then washed with 
distilled H20 and tissues dehydration obtained through ascending series ethanol (70%, 
90%, 100%). After tissue dehydration slides were diafanized in Toluene for 20 minutes 
and samples embedded in paraffin blocks. Colon tissues were finally sectioned with a 
microtome at 4µm thickness and stained with hematoxylin and eosin (H&E) or used for 
immuno-staining. 
3.2.2 Hematoxylin & Eosin staining 
For histological analysis, formalin-fixed and paraffin-embedded colon sections of  4 µm 
thickness were de-waxed in toluene for 10-15 min and then rehydrated in descending 
series of ethanol solutions (100%, 95%, 70% and then in water). The de-waxed, 
rehydrated colon sections were stained with Hematoxylin & Eosin (H&E) using 
standard protocol and analyzed by pathologists in blinded fashion. 
3.2.3 Histological assessment of colonic inflammation  
Sections from each mice were microscopically examined for histopathologic changes 
associated with inflammation using the following scoring system. For the analysis of 
inflammatory cell infiltration: 0) none 1) minimal 2) moderate 3) severe. For 
inflammation extent: 0) none 1) mucosa, 2) mucosa and confluence of cells in 
submucosa 3) transmural inflammation. Cryptitis, which was defined as the presence of 
neutrophils within the crypt epithelium, and crypt loss were also evaluated according 
the following criteria: 1) 1/3 of affected crypts 2) 2/3 of affected crypts 3) crypt lost 
with intact epithelium surface 4) crypt lost with changes of epithelial surface structures.  
Percent area involvement was defined as: 0) none  1) 1-25%, 2) 26-50%, 3) 51-75%, 4) 
76-100%. Histology score was determined by multiplying the percent involvement for 
each of the three previous described histological features by the percent area of colonic 
involvement (Poudyal et al., 2012).   
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3.2.4 Immunohistochemistry  
For immunohistochemical (IHC) analysis, formalin-fixed and paraffin-embedded colon 
sections were de-waxed in toluene for 20 min, re-hydrated in 100% Ethanol for 5 min 
and subjected to endogenous peroxidase inhibition for 20 minutes at 4°C  in 
methanol/H2O2 mixture. Slides were after re-hydrated  with a 96% to 70% ethanol 
gradient and  washed in distilled water for 2 min. Antigen retrival was performed in 
pressure cooker with citrate buffer (pH 6.0) at 120°C for 15 min. For Ki-67 slides were 
washed in PBS and unspecific background was blocked with blocking buffer (10% 
normal goat serum in PBS). The staining was performed with an avidin-biotin reaction 
applying a diluted primary mouse monoclonal antibody (1:400 in PBS o/n  at 4° C)  
(clone MM1, Leica Microsystems, Milan, Italy). After washing primary antibody, a 
biotinylated secondary antibody  (Vector Laboratories, Burlingame, CA) was 
subsequently applied (1:500 for 1h RT) and the reaction was revealed with DAB (3,3' 
Diaminobenzidine) (Sigma-Aldrich), using hematoxylin as a counterstaining. For β-
catenin, slides were processed using the non-biotin-amplified complex (NovoLink 
Polymer Detection System, Leica Microsystem). Briefly, according to the 
manufacturer's instruction slides were blocked with Novocastra
TM
 Protein Block for 5 
minutes in a wet chamber in order to minimize the non-specific binding of primary 
antibody, rinsed twice with TBS 1X, and then incubated with a primary mouse 
monoclonal anti-beta-catenin antibody (1: 2.500 o/n at 4°C) (clone 14, BD Biosciences, 
Buccinasco, Italy). After washing with TBS, the slides were  incubated with Post 
primary Block (Rabbit anti-mouse IgG) for 30 min at RT, rinsed in TBS and then 
incubated with Novolink polymer for 30min. The peroxidase activity was revealed 
using DAB as substrate, prepared from DAB Chromogen and  Novolink
TM
 DAB 
substrate buffer. To stop the reactions slides were rinsed in distilled water, 
counterstained with hematoxylin, dehydrated through an ethanol series and 
coverslipped. The Ki-67 proliferation index was calculated as the ratio between positive 
nuclei and total number of nuclei per crypt analyzed. β-catenin nuclear positivity was 
quantified on at least 50 crypts per sample. 
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3.3 TUNEL assay  
Apoptosis was evaluated through the DeadEnd
TM
 Fluorimetric TUNEL System 
(Promega, Milan, Italy). This system allows the identification of apoptotic cells through 
the evaluation of DNA fragmentation, a biochemical hallmark of late programmed cell 
death. During apoptosis the cleavage of genomic DNA generate double-stranded DNA 
fragments (DSBs) with accessible 3'-hydroxyl (3'-OH) groups making it possible the 
enzymatic addition of fluorescently labeled nucleotides by Terminal Deoxynucleotidyl 
transferase (TdT) that can be revealed by fluorescence microscopy. For carrying out the 
TUNEL assays, according to the manufacturer's recommendations, tissues sections were 
de-waxed  in xylene and rehydrated through a reverse ethanol series (100%, 95%, 70%). 
The slides were subsequently fixed in formaldehyde (4% in  PBS) for 15 minutes at RT, 
permeabilized with Proteinase K solution incubation (20 µg/ml diluted in Tris-HCl 50 
mM pH 8.0) at RT  for 10 minutes and subsequently washed twice with PBS for 5 
minutes. After repeating fixing and washing step, tissues sections were treated with 
equilibration buffer at RT for 10 minutes and incubated with nucleotide mix and rTdT  
buffer for 1 hour at 37°C in a humified chamber. As a positive control, slides were 
treated  with DNaseI (GE HEALTHCARE) for 10 minutes to cause DNA fragmentation 
and prepared as previously described . As a negative control slides were incubated with 
nucleotide mix without  rTdT enzyme. To stop the reaction, slides were incubated in 
SSC 1X and washed with PBS to remove unbound fluorescent dNTPs.  All the slides 
were mounted adding the DAPI (Prolong Gold) nuclear stain in mounting medium and 
analyzed by fluorescence microscopy. Tunel positive cells were counted in at least 10 
randomly selected fields (magnification 40X).  
3.4 Mucosal fatty acid analysis 
The PUFAs introduced with the diet were able to be incorporated in cell membranes as 
lipid component modulating the biological features (e.g., fluidity, thickness and 
deformability) and subsequently the biological functions of the membrane components 
(Rajamoorthi et al., 2005). These fatty acids, competing as substrates for  
cyclooxygenases and lipoxygenases enzymes, may affect their activity and subsequently 
the production of signalling molecules, named eicosanoids, with opposite physiological 
MATERIALS & METHODS 
50 
 
functions. The membrane fatty acid composition was analyzed through gas-
chromatography mass spectrometry (GC-MS) on mice colonic tissues as described 
below .  
3.4.1 Tissues homogenization 
For tissues homogenization, frozen colonic tissues fractions were pulverized in 12x75 
glass tubes in  500 μl of PBS in ice and the tissues on the homogenizer blades were 
washed with 1 ml of chloroform-methanol mixture (CHCl3/MetOH 1:2 v/v) in  the 
same tube. In order to avoid cross contaminations among specimens, the homogenizer 
blade was washed with ethanol, water and PBS for each sample.  
3.4.2 Lipid extraction  
Subsequently, in order to proceed with lipid extraction, the samples were transferred 
with Pasteur pipettes in SOVIREL extraction tubes, washed with 3 ml of  chloroform-
methanol mixture (CHCl3/MetOH 1:2 vol/vol)  in presence of  the antioxidant butylated 
hydroxytoluene (BHT 0.01%) and agitated under shaking for 30 minutes at room 
temperature. After thorough mixing, samples were centrifuged for 10 minutes at 2.000 x 
G at room temperature and the upper solvent layer was transferred in a new SOVIREL 
tube. The extraction was repeated with 2 ml of solvent and the supernatant layer 
combined. The solvent fraction was then re-extracted with 3 ml of CHCl3/H2O (1:1 - 
BHT 0.01%), vortexed and spinned, (2000 x G, 5 min, 25°C); the inferior solvent phase 
was transferred to a new SOVIREL tube and frozen at –20°C up the transmethylation. 
3.4.3 Transesterification  
The solvent phase was evaporated under a stream of nitrogen and 2 ml of KOH/MetOH 
solution  (0.5M + 0.01% BHT) were added, the tubes carefully closed and heated at 
80°C for 10 minutes in a dry thermal block. When the solution was at room  
temperature 1 ml of BF3: MetOH solution was added to each sample and the tubes 
wormed at 80°C in the dry thermal block for 10 minutes to develop a Methyl Ester mix. 
3.4.4 Extraction of Methyl Esters 
Methyl Esters were extracted adding 3 ml of  hexane to each sample. The samples were 
then vortexed for 30 sec and spinned at 2000xG for 10 min at room temperature. The 
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supernatant solvent phase has been carefully recovered and transferred to a new glass 
tube. This extraction process was after repeated with other 2 ml of hexane. The hexane 
was evaporated under a stream of nitrogen to reduce the volume to 1 ml which was then 
transferred to a glass auto sampler vial. The tube was washed with 500 µl of hexane and 
the sample evaporated to dryness, redissolved with 20 μl of ciclohexane for the analysis 
and frozen at –20°C until injected. 
3.4.5 GC-MS conditions 
GC MS analysis was carried out using an Agilent HP6890 GC with PTV Injector and 
MS is an HP5973 mass detector;  The column is SUPELCO SPTM-2330 (30mt x 0.25 
mm x 0.2 μm film thickness)  column. Carrier gas is Helium at 0.5 ml/min, in constant 
pressure mode;  Injection cycle is in Solvent Vent mode, starting from 60° and ramps to 
220°C ; column  temperature was from100°C for 1.25 min, then was programmed to 
rise to185°C at 3 0 °C and to 205°C at 5 °C/min; total GC run time was 32min 1-4 μl 
samples was injected to GC-MS analysis. MS operates in EI mode, at 70 eV; 
Quadrupole temperature is 150°C; Ion source and GC interface were respectively 
230°C, 280°C; Full data scan from m/z 40 to m/z 550.  
3.4.6 Data processing and quantification  
Retention times and peak area of analytes were determined by the Enhanced Data 
Analysis integration system of G1701 DA Agilent software. The percentage of analytes 
were calculated from the sum of the peak area of all analytes of interest using the 
following equation: 
                                         
                                      Analyte Peak area * 100 
Analyte percentage =      _______________________________ 
                                              (Σ areas of all identified peaks) 
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3.5 Urinary PGE-M excretion analysis  
PGE-2 is one of the prevalent eicosanoids produced from arachidonic acid by 
cyclooxygenases (COX-1 and COX-2) enzymes in presence of an inflammatory milieu. 
Given the very short half-time of PGE-2 in the circulatory system, the tetranor 11α-
hydroxy-9, 15-dioxo-2, 3, 4, 5-tetranor-prostane-1, 20-dioic acid (known as PGE-M), 
the major urinary  metabolite of PGE-2, represents a well validated marker for the PGE-
2 biosynthesis determination "in vivo" (Murphey et al., 2004). In this work PGE-M 
levels were assayed on pooled urinary samples deriving from each animal in a given 
treatment using a liquid chromatography (LC)/tandem MS (LC-MS/MS) system 
according to the protocol described by Murphey et al (Murphey et al., 2004).  
3.5.1 Samples preparation, PGE-M extraction and purification 
Pooled urine samples (1ml) were acidified to pH 3 using 1M HCl. Endogenous PGE-M 
was derivatized incubating the sample with 0.5 ml of 16% (w/v) methyloxime HCl in 
1.5 M of sodium acetate buffer (pH 5) for 1 hour. The assay internal standard was 
prepared converting the chemically synthesized PGE-M to a [
2
H6] O-methyloxime 
derivative by treatment  with [
2
H3] O-methoxyamine HCl. The resulting methoximated 
PGE-M was extracted with 10 ml of water (pH 3). Samples were purified by solid phase 
extraction using a C-18 Sep-Pak cartridge (Waters, Milford, MA, USA) preconditioned 
with 5 ml methanol and 5 ml of water (pH 3). The samples were applied to the cartridge 
and  then washed with 20 ml of water (pH 3) and 10 ml of heptane. The analytes were 
then eluted from the cartridge using 5 ml ethyl acetate and dried under a continuous 
stream of nitrogen at 37°C. The internal standard of [
2
H6] O-methyloxime PGE-M was 
then added and the eluate collected and dried under the same conditions. The resulting 
fraction was reconstituted in 50 µl of mobile phase A (95:4:9:0:1 (v/v/v) 5 mM 
ammonium acetate: acetonitrile: acetic acid) and filtered through a 0.2-micron Spin X 
filter (Corning, NY, USA). 
3.5.2  Sample analysis by LC/MS/MS  
Separation by LC was performed using an Acquity Ultra Performance LC
TM 
(UPLC 
TM
) 
BEH C8 Column, 2,1 X 100 mm, 1.7 µm (Waters, Milford, USA). Mobile phase A was 
95:5, 0,1% ( v/v) acetic acid: acetonitrile, and mobile phase B was 50:50, 0,1% (v/v) 
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acetic acid: acetonitrile. Samples were separated by a gradient of 98-40% mobile phase 
A over 15 min at flow rate of 300µl/min prior to delivery to a Quattro Premier 
TM
 XE 
(Waters Corp, Milford, USA) bench-top tandem quadrupole mass spectrometer operated 
in multiple reaction monitoring (MRM) mode. Samples were ionized through ESI using 
nitrogen as source for both sheath and auxiliary gas setted at 60 psi and 7L/min, 
respectively. The mass spectrometer was operated in the negative ion mode with a 
capillary temperature of 210°C, a spray voltage of 3.0 kV, and a cone voltage of 19V. 
MRM channels were established for PGE-M (m/z 385.2 > 336.2) and the internal 
standard PGE-Md6 (m/z 391.2 > 339.2) (Cayman Chemical, Ann Arbor, MI). 
Quantification of endogenous urinary PGE-M was performed against the internal 
standard with calibration using 10-100 ng/ml authentic PGE-M. The limit of detection 
was 1ng/ml. Data were expressed after correction for urinary creatinine concentrations 
and reported as nanongram (ng) of PGE-M per milligram (mg) of creatinine. The 
urinary creatinine concentration was measured by HPLC using the method by 
Hewavitharana and Bruce (Hewavitharana and Bruce, 2003).   
      
3.6 Circulating cytokine analysis 
Circulating cytokine levels were determined in serum samples using a Bio-Plex 
multiplexed bead-based sandwich immunoassay (Bio-Rad Laboratories, Milan, Italy). 
This system relies on the calculation of the fluorescence emission signal resulting from 
the binding of a biotinylated antibodies with the complex constituting by an antibody-
coupled fuorescent dyed bead and a specific cytokine. The reaction is revealed using 
streptavidin-phycoerythrin (streptavidin-PE), which binds to the biotinylated detection 
antibodies. The Bio-Plex Manager™ software automatically calculate cytokines 
concentrations in the sample using a standard curve derived from a recombinant 
cytokine standard. The use of the different colour beads-set allows the discrimination 
and simultaneous quantification of multiple cytokines in the same sample. In our 
experiments we used a multiplex cytokines assay (Bio-Plex Bio-Rad Laboratories, 
Milan, Italy) which allow the detection of six mouse cytokines: IL-6, IL-10, IL1β, IL-
17,IFN-γ and TNF-α. Serum samples were obtained from whole blood after 
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centrifugation at 1.000 x g for 15 min at 4°C. The analysis was performed pooling 
serum samples from animals in each arm. According to the manufacturer instructions, 
the lyophilized cytokines standards were diluted with 500 µl of  the appropriate standard 
diluent, vortexed gently and incubated on ice for 30 min. Reconstituted cytokine 
standards were used to produce an eight-point standard curve with a fourfold (1:4) 
dilution between each point. Serum samples were also diluted with the specific Bio-Plex 
mouse sample diluent (1:4). 50 μl of cytokine standards or samples were added to each 
well of a 96-well filter plate and incubated with 50 μl of coupled beads for 30 min at 
room temperature under shaking (850 +/- 50 rpm). Plates were then washed by vacuum 
filtration three times with 100 μl of Bio-Plex wash buffer, 25 μl of diluted detection 
biotinylated antibody were added, and plates were incubated for 30 min at room 
temperature with shaking. After three filter washes, 50 μl of streptavidin-PE were 
added, and the plates incubated for 10 min at room temperature under shaking. Finally, 
plates were washed by vacuum filtration three times, beads suspended in Bio-Plex assay 
buffer, and samples analyzed on a Bio-Rad 96-well plate reader using the Bio-Plex 
Suspension Array System and Bio-Plex Manager software (Bio-Rad Laboratories, 
Hercules, CA). Each sample was tested in duplicate, and cytokine standards supplied by 
the manufacturer were run on each plate. 
3.7 Gene expression analysis 
3.7.1 RNA extraction  
Total RNA was extracted from distal colon segments. Briefly, tissues were 
homogenized in Trizol® Reagent (Life Technologies, Monza, Italy) and RNA 
extraction was performed following the manufacturer's instructions. RNA concentration 
and purity was evaluated by measuring the absorbance (optical density, OD) at 260 nm 
in relation to the absorbance at 280 nm (OD 260/280) or 230 nm (OD 260/230) 
respectively for protein or ethanol contamination using NanoDrop spectrophotometer 
(Thermo Scientific). 
3.7.2 qRT-PCR: Taqman Gene Expression Assay 
Total RNA (2 µg) was reverse transcribed to cDNA using a GoScript 
TM
 Reverse 
Transcription System (Promega) according to the manufacturer’s suggested protocol. 
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Briefly, after heating of combined RNA and Oligo(dT)15 primers at 70°C for 5 minutes 
followed by a step on ice for other 5 minutes, the reverse transcription mix was 
prepared and added to primer/RNA mix in a final volume of 20 µl. The reverse 
transcription mix was composed of 4.0 µl of GoScript™ reaction buffer, 4.0 µl of 
MgCl2 25 mM, 1.0 µl of PCR nucleotide mix 10mM, 0.5 µl of Recombinant RNasin® 
Ribonuclease Inhibitor (40 U/ µl), 1.0 µl of GoScript™ Reverse Transcriptase and 4.5 
µl of nuclease free water. After annealing at 25°C for 5 minutes, the extension reaction 
was performed at 42°C for 60 minutes and reverse transcriptase was then inactivated at 
70°C for 15 minutes. Finally, the obtained  cDNA was stored at -20°C until the use. For 
quantitative real-time PCR the cDNA was diluted 1:3 and 2 µl of diluted cDNA was 
used in duplicate in 20 µl total volume using TaqMan Gene Expression Master Mix and 
TaqMan Gene Expression Assays (Life Technologies, Monza, Italy) for genes listed in 
Table 1 . The qRT-PCR reaction was performed on Stratagene MX3000P QPCR 
thermal cycler machine (Agilent Technologies, Milan, Italy) as follows: 50ºC for 2 min 
for Uracil-DNA Glycosylase (UDG) incubation, 95°C for 10 min for AmpliTaq Gold 
enzyme activation followed by 45 cycles of denaturation at 95°C for 15s and 
annealing/extension at 60°C for 1 min. Fold induction levels for each gene were 
obtained using the 2-
ΔΔCt
 method by normalizing against GAPDH used as endogenous 
control. Fold changes values were compared to the healthy mice group.  
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Table 1 TaqMan assays employed for qRT–PCR analysis 
TaqMan Assay ID Gene symbol Gene name (mouse) 
Mm00496902-m1 Jag1 Jagged1 
Mm01342805-m1 Hes1 Hairy and enhancer of split  1 
Mm00476035-s1 Atoh1 Atonal homolog 1 
Mm00482529-s1 Nrarp Notch-regulated ankyrin repeat protein 
Mm00446190-m1 IL-6 Interleukin 6 
Mm00443260-g1 TNF-α Tumor necrosis factor-alpha 
Mm00434228-m1 IL-1β Interleukin 1 beta 
Mm01168134-m1 IFN-γ Interferon gamma 
Mm99999915-g1 Gapdh Glyceraldehyde-3-phosphate dehydrogenase 
 
3.7.3 qRT-PCR: Taqman miRNA Expression Assay 
Reverse transcription reaction for the Taqman miRNA Assays (Life Technologies) was 
performed using the Taqman microRNA Reverse Transcription Kit (Life Technologies) 
with 150 ng of total RNA, per 15 µl reaction. The 1X reverse transcription mix was 
composed of 0.15µl 100mM dNTPs, 1µl Multiscribe Reverse Transcriptase 50U/µl, 1.5 
µl 10X reverse transcription buffer, 0.19µl RNAse inhibitor 20U/µl and 4.16µl of 
nuclease free water, 3µl of 5X specific miRNA reverse transcription primers, and 5µl of 
sample RNA, making a total volume of 15µl. Specific supplied primers for snoRNA202 
and miR-34a  were used. Reverse transcription thermocycling parameters were as 
follow: 16°C for 30min, 42°C for 30min, 85°C for 5min and a final holding temperature 
of 4°C. The resultant cDNA were quantified in qRT-PCR in duplicate in 20 µl total 
volume using  TaqMan® Universal PCR Master Mix, no AmpErase® UNG (Life 
Technologies, Monza, Italy) and TaqMan® MicroRNA Assays  (Life Technologies, 
Monza, Italy) with the specific probes for each miRNA assay (snoRNA202 Assay ID: 
001232; mmu-miR-34a Assay ID: 000426). The qRT-PCR reaction was performed on 
Stratagene MX3000P QPCR thermal cycler machine (Agilent Technologies, Milan, 
Italy) as follows: 95°C for 10 min for AmpliTaq Gold enzyme activation followed by 
45 cycles of denaturation at 95°C for 15s and annealing/extension at 60°C for 1 min. 
Fold induction levels for miR-34a were obtained using the 2-
ΔΔCt
 method by 
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normalizing against snoRNA202 used as endogenous control. Fold changes values were 
compared to the healthy mice group. 
3.8 Gut microbiota analysis 
The mouse intestinal microbiota composition was characterized on pooled faecal 
samples deriving from each animal in a given  treatment using a validated phylogenetic 
DNA microarray platform High Taxonomic Fingerprint microbiota Array (HTF-
Microbi.Array) (Candela et al., 2010). This approach is based on Ligase Detection 
Reaction-Universal Array (LDR-UA) allowing the identification of 16S rDNA of 33 
phylogenetically related groups corresponding to the 95% of the mammalian gut 
microbiota. For the LDR reaction two pairs of oligonucleotide probes and a 
thermostable DNA ligase were used with previously PCR-amplified DNA products. The 
two probes are designed as a pair of adjacent oligonucleotides specific for each target 
sequence: a probe specific for the variation, called "Discriminating Probe" or DS which 
carries a fluorophore Cy3 at 5' and a second probe, named "Common Probe" or CP, 
starting one base 3'-downstream of the DS and carries a 5'-phosphate group and a 
unique sequence named cZipCode at its 3'end. This LDR technology is based on the 
high discriminating power of the DNA ligation enzyme which will occur only in 
presence of a perfect match between a specific template and a particular pair of probes 
DS and CP.  
3.8.1 DNA extraction from faecal samples 
Total DNA from faecal samples obtained at sacrifice was extracted by using QIAmp 
DNA Stool Mini Kit (Qiagen, Milan, Italy) with µa modified protocol as described by 
Candela et al. (Candela et al., 2010). 250 mg of  pooled faeces  for each arm were 
suspended in 1 ml of lysis buffer. Then 0.5 g of Zirconia beads and four 3 mm glass 
beads were added to the samples and placed into the instrument FastPrep24 (MP 
Biomedical, Irvine, CA, USA) performing 3 cycles of rotation at a speed of 5.5 m / s for 
3 minutes allowing cell lysis and recovery of nucleic acids. All samples were heated at 
95 °C for 15 minutes and then centrifuged at maximum speed for 5 minutes to pellet 
stool particles. Supernatants were collected, supplemented with 260 µl of 10 M 
ammonium acetate, incubated on ice for 5 min and centrifugated at maximum speed for 
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10 minutes. One volume of isopropanol was added to each supernatant and then 
samples were incubated on ice 30 minutes. The precipitated nucleic acid were collected 
by centrifugation at full speed for 15 minutes and washed with EtOH 70%. 
Subsequently, the pellets were resuspended with 100 µl of TE buffer and incubated with 
2 µl of DNase-free-RNase (10 mg/ml) at 37°C for 15 minutes. DNA purification with 
QIAmp Mini Spin columns and protein removal by Proteinase K treatment were 
performed following the kit protocol. Purificated DNA were quantified by using 
NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE). 
3.8.2 PCR amplification of 16S rDNA gene  
A nearly full- lenght portion of 16S ribosomal DNA was performed using universal 
forward primer 16S27F (5'-AGAGTTTGATCMTGGCTCAG-3') and reverse primer 
r1492 (5'-TACGGYTACCTTGTTACGACTT-3'). PCR amplifications were performed 
with Biometra Thermal Cycler T Gradient (Biometra, Germany). The reaction mixtures 
included 500 nM concentrations of each primer, 200 μM concentrations of each 
deoxynucleoside triphosphate, 10 mM Tris-HCl (pH 8.8), 1.5 mM MgCl2, 50 mM KCl, 
0.1% (wt/vol) Triton X-100, 0,5 U of DNAzyme DNA polymerase II (Finnzymes, 
Espoo, Finland), and 50 ng of genomic DNA in a final volume of 50 μl.  PCR 
conditions are as follows: 95°C for 5 min, 35 cycles of denaturation at 95°C for 60 s, 
annealing at 60°C for 30s, elongation at 72°C for 90 sec and one final step at 72°C for 
10 min. PCR products were purified using the High Pure PCR Cleanup Micro Kit 
(Roche, Mannheim, Germany) and eluted in 30 µl of sterile water and quantified with 
NanoDrop.  
3.8.3 Ligation Detection Reaction  
The PCR products were used as template for the Ligation Detection Reaction (LDR). 
The LDR was carried out in a final volume of 20 μl containing 20 mM Tris-HCl (pH 
7.5), 20 mM KCl, 10 mM MgCl2, 0.1% NP-40, 0.01 mM ATP, 1 mM dithiothreitol, 
250 fmol of each discriminating probe, 250 fmol of each common probe, 10 fmol of the 
hybridization control, and from 0.5 to 100 fmol of purified PCR products. After the 
reaction mixture was preheated for 2 min at 94°C and centrifuged for 1 min, 4 U 
of Pfu DNA ligase (Stratagene, La Jolla, Calif.) was added. The LDR was performed 
using a thermocycler Thermal Cycler Gradient T (Biometra) by setting the following 
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program: initial denaturation at 94 ° C for 5 minutes, 40 cycles at 94 ° C for 30 seconds, 
60 ° C for 4 minutes and a cycle at 94 ° C for 2 minutes. 
3.8.4 Array hybridization of the LDR products 
The hybridization mixture was prepared in a final volume of 65 µl containing 20 μl of 
LDR mixture, 5× SSC, and 0.1 mg of salmon sperm DNA/m and distilled H2O. After 
heating at 94°C for 2 min and chilling on ice, the hybridization mixture was applied to 
the slide, on which the sixteen arrays were separated by Press-To-Seal silicone isolators 
(1.0 × 9 mm; Schleicher & Schuell BioScience, Dassel, Germany). The hybridization 
was carried out at a temperature of 65 ° C in the dark with shaking at 40 rpm for an hour 
and 30 minutes. Afterwards the slides were washed at 65°C for 15 minutes in 
prewarmed SSC 1X  preheated to 65 ° C and dried in a JA14 tube by centrifugation for 
3 minutes at 800 rpm. 
3.8.5 DNA Array  
The HTF-Microbi.Array allows the identification and approximate relative 
quantification of 16S rDNA of 33 phylogenetically related microbial groups 
phylogenetically of the intestinal microbiota . The targeted intestinal bacteria revealed 
by HTF-Microbi.Array were showed in Table 2 
3.8.6 Data Acquisition 
The fluorescent signals were acquired at a 5-μm resolution by using a ScanArray 4000 
laser-scanning system (PerkinElmer Life and Analytical Sciences, Boston, Mass.) with 
a green laser for Cy3 dye (λex, 543 nm; λem, 570 nm). ScanArray Express v 4.0, was 
used to quantify the fluorescent intensity of the spots. Fluorescence intensity were 
normalized on the basis of the synthetic ligation control signal. Relative abundance of 
each bacterial group was obtained by calculating the relative fluorescence contribution 
of the corresponding HTF-Microby Array probe as a percentage of the total 
fluorescence.   
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Table 2 Microbial groups detected by HTF-Microbi.Array 
 
Bacterial group Taxonomic level  Cluster  Order Division 
Bacteroides/Prevotella Cluster Bacteroides/Prevotella Bacteroidales Bacteroidetes 
Ruminococcus bromii Sub cluster Cl IV Clostridiales Firmicutes  
Ruminococcus albus Sub cluster Cl IV Clostridiales Firmicutes  
Faecalibacterium prausnitzii Sub cluster Cl IV Clostridiales Firmicutes  
Oscillospira guillermondii Sub cluster Cl IV Clostridiales Firmicutes  
Clostridium IX Cluster Cl IX Clostridiales Firmicutes  
Veilonella Species Cl IX Clostridiales Firmicutes  
Clostridium XIVa Cluster Cl XIVa  Clostridiales Firmicutes  
Eubacterium rectale Species Cl XIVa Clostridiales Firmicutes  
Bifidobacteriaceae Family Bifidobacterium Bifidobacteriales Actinobacteria 
B. longum Species Bifidobacterium Bifidobacteriales Actinobacteria 
Lactobacillaceae Family Lactobacillaceae Lactobacillales Firmicutes  
L. plantarum Species Lactobacillaceae Lactobacillales Firmicutes  
L. casei Species Lactobacillaceae Lactobacillales Firmicutes  
L. salivarius Species Lactobacillaceae Lactobacillales Firmicutes  
Bacillus clausii Species Bacillaceae Bacillales Firmicutes  
Bacillus subtilis Species Bacillaceae Bacillales Firmicutes  
Streptococcacea Family Streptococcaceae Lactobacillales Firmicutes  
Fusobacterium Genus Fusobacteriaceae Fusobacteria Fusobacteria 
Akkermansia Genus Verrucomicrobiae Verrucomicrobiae Verrucomicr obia 
Cyanobacteria Family Cyanobacteria Cyanobacteria Cyanobacteria 
Clostridium XI Cluster Cl XI Clostridiales Firmicutes  
Clostridium diffcile Species Cl XI Clostridiales Firmicutes  
Clostridium I e II Cluster Cl I e II Clostridiales Firmicutes  
Clostridium perfringens Species Cl I e II Clostridiales Firmicutes  
Enterococcus faecalis Species Enterococcales Lactobacillales Firmicutes  
Enterococcus faecium Species Enterococcales Lactobacillales Firmicutes  
Staphylococcus Genus Staphylococcaceae Bacillales Firmicutes  
Bacillus cereus Species Bacillaceae Bacillales Firmicutes  
Enterobacteriaceae Family Enterobacteraceae Enterobacterales Proteobacteria 
Yersinia enterocolitica Species Enterobacteraceae Enterobacterales Proteobacteria 
Proteus Genus Enterobacteraceae Enterobacterales Proteobacteria 
Campylobacter Genus Campylobacteraceae Campylobacterales Proteobacteria 
 
 
MATERIALS & METHODS 
61 
 
 
3.9 Statistical analysis 
Data were reported  as mean ± SEM. One-way ANOVA was used to analyze continuous 
variables followed by Turkey's for comparison among groups. Tumor incidence was 
evaluated by Fisher's exact test. Data analysis was performed using Graph Pad Prism 
5(GraphPad software, La Jolla, CA). For the gut microbiota experiments, statistical 
analysis was performed using SigmaStat v 3.5 (Systat Sofware, San Jose, CA) and R 
statistical software. P values less than 0.05 were considered statistically significant. 
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4. RESULTS 
4.1 Food intake, body weight and mortality rate during the experimental protocol  
Food intake was monitored daily. Animal body weight was evaluated three times per 
week. No statistical differences were appreciated in term of food intake (Figure 9) and 
body weight (Figure 10) among the diets arms during the AOM-DSS experimental 
protocol. 
 
 
Figure 9 Food intake in the AOM-DSS protocol  No significant changes were observed in 
terms of food intake among the three different groups. Data are means ± SEM.  
 
 
Figure 10  Body weight during the AOM-DSS protocol   No significant changes in body 
weight were observed among the three different groups during the protocol Data are means ± 
SEM.  
 
RESULTS 
63 
 
Importantly, no statistical differences were found in terms of animal mortality among 
the three different groups of treatment (7/20 in the control group and 9/20 in the 
promotion and initiation arms). 
4.2 EPA-FFA protect from inflammatory carcinogenesis in AOM-DSS mouse 
model 
In this study, colitis associated colorectal cancer (CAC) was induced by a single 
injection of AOM followed by repeated administration of DSS according to a well 
established protocol (Tanaka, 2012), (Neufert et al., 2007a). In order to investigate the 
effect of EPA-FFA on the initiation and promotion of CAC, we performed a feeding 
protocol in AOM-DSS mouse model background. Control group fed a balance diet 
(AIN76A) for the entire duration of the study. Promotion and Initiation arms were fed 
with a balance diet (AIN76A) in which 1% of corn-oil was substituted with 1% EPA-
FFA. Our results showed an important chemopreventive effect of EPA-FFA on tumor 
development in both arms fed with EPA-FFA diet respect to the Control arm. Indeed, 
macroscopic and histologically analysis revealed that all mice except one fed with the 
Control diet, developed colon adenocarcinoma at the end of the study, while only three 
animals in the promotion and four in the initiation groups developed cancers. Lesions 
were mainly located in the distal to middle colon, while no tumors were found in the 
proximal section of the colon in either group of animals. The reduction of tumor 
incidence encountered was respectively of 72.7% in the promotion group (p = 0.0003 
vs. Control arm) and 63.6% in the initiation group respect to the Control arm (p = 
0.0013 vs. Control arm) (Figure 11A). Moreover, we found that EPA-FFA diet was able 
to significantly decrease tumor multiplicity (number of lesions/mouse) when compared 
to the Control diet. We counted a reduction of 78.2% and 69.8% in the number of 
lesions for each mouse respectively in the promotion and initiation arms respect to the 
Control group (p < 0.0001 for promotion vs. Control and p < 0.001 for initiation vs. 
Control) (ANOVA p = 0.002) (Figure 11B). In addition, the maximum polyps size 
(mm) was also significantly higher in mice feeding the Control diet respect the 
promotion and initiation groups in whom the average tumor size resulted decreased by 
75.7% and 63.9% respectively (p < 0.001 for promotion vs. Control and p < 0.05 for 
initiation vs. Control) (ANOVA p = 0.002) (Figure 11C) (Table 3). Representative 
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images of H&E stained colon sections at the end of the AOM/DSS protocol were 
reported in Figure 12.  
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Figure 11 Effect of EPA-FFA on tumor incidence, multiplicity and size A) Tumor 
incidence, B) Tumor multiplicity and C) Max tumor size in Control group and in EPA-FFA 
feeding groups at the end of the AOM/DSS protocol. Polyp incidence was calculated as 
percentage of animals with tumors in each arm using Fisher’s exact test. Tumor multiplicity 
(number of lesions/ mouse in each arm) and max tumor size (mm) were reported as means ± 
SEM and analyzed using one-way ANOVA followed by Turkey’s for multiple comparison. * P 
< 0.05; ** P < 0.001; *** p < 0.0001. 
 
Table 3 Effect of experimental diets on tumor incidence, multiplicity and size  
Group N 
% Animals with colon 
tumors  
N° tumors per 
animal  
Average size of tumors 
(mm
2
)  
Control 13 92,3 5 ± 0,75 10,08  ± 1,17 
Promotion 11 27,3 1,18 ±  0,72 2,55 ± 1,66 
Initiation 11 36,4 1,64 ± 0,75 3,64 ± 1,68 
 
Values are reported as means ± SEM.  
Statistical variations among the feeding protocols were reported in Figure 11 
 
 
Figure 12 Representative images of H&E stained colon sections at the end of the AOM/DSS 
protocol A) Control B) Promotion C) Initiation (Ctrl n = 13, Promotion and Initiation n = 11).  
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4.3 EPA-FFA increases apoptosis, reduces cell proliferation and nuclear β-catenin 
in AOM-DSS-treated mice 
Given the important chemopreventive effect encountered in mice feeding EPA-FFA 
diets, we speculate that changes in apoptosis or cell proliferation may contribute to 
explain the differences in tumor development among the diets groups. Apoptotic cells 
were evaluated using in situ terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) staining. Both arms feeding the EPA-FFA diet showed a significant 
increase of apoptosis rate compared to the Control group. We found an increase in the 
number of tunel positive cells of 43.1% in the promotion and 55.1% in the initiation 
groups, respectively (p < 0.05 for promotion vs. Control; p < 0.001 for initiation vs. 
Control) (ANOVA p = 0.003) (Figure 13A). Next, to determine the impact of EPA-FFA 
on cellular proliferation, Ki-67 immunoistochemistry (IHC) was performed. Ki-67 
positive cells on total number of nuclei/crypt were counted and averaged. We observed 
that nontumorigenic colonic epithelium in the promotion and initiation protocols was 
characterized by a marked reduction of cell proliferation as compared to the Control 
arm. The percentage of Ki-67 positive cells reduction detected was 24% and 27.7% in 
the promotion and initiation arms, respectively (both groups vs. Control p < 0.0001) 
(ANOVA p < 0.0001) (Figure 13B). Subsequently, since it is known that β-catenin 
signaling activation is a critical event in colorectal carcinogenesis (Sellin et al., 2001) 
and the upregulation of nuclear β-catenin was reported in AOM-DSS mouse model(Lu 
et al., 2014), we decided to evaluate whether EPA-FFA is able to prevent this 
phenomenon. Immunohistochemical analysis of β-catenin was carried out in each arm 
of treatment quantifying nuclear positivity on at least 50 crypts for sample. Quantitative 
analysis revealed a significant lower nuclear translocation of β-catenin in both EPA-
FFA treated arms showing a reduction of 58% in the promotion and of 68.2% in the 
initiation arms when compared to the Control group (p < 0.0001 for both groups vs. 
Control) (ANOVA p < 0.0001) (Figure 13C).    
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Figure 13  Effects of EPA-FFA on apoptosis, cell proliferation and nuclear β-catenin 
A) Representative TUNEL staining of colon sections from mice feeding the Control diet or 
EPA-FFA diets in the AOM-DSS protocol. EPA-FFA significantly increases tunel positive cells 
as compared to the control group. Histogram show average number of TUNEL positive cells per 
field (Ctrl n = 13, Promotion and Initiation n = 11)  B) Sections from distal colon of AOM-DSS 
treated mice following different feeding protocols stained with Ki67 antibody for cell 
proliferation analysis. EPA-FFA significantly reduces Ki-67 nuclear staining in both promotion 
and initiation arms as compared to the control. Histogram show average number of Ki-67 
positive nuclei/total nuclei (Ctrl n = 13, Promotion and Initiation n = 11)   C) β-catenin nuclear 
staining in Control and EPA-FFA feeding groups of AOM-DSS treated mice. EPA-FFA arms 
showed significant less nuclear β-catenin translocation as compared to control. Histogram show 
average number of β-catenin positive nuclei/crypt (Ctrl n = 13, Promotion and Initiation n = 11)  
Data represent means ± SEM P < 0.05; ** P < 0.001; *** p < 0.0001.   
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4.4 EPA-FFA modulate colonic fatty acid composition in AOM-DSS-treated mice 
To assess the success of the feeding protocol, and in order to establish the effect of 
EPA-FFA diets on fatty acids composition, the incorporation of most representative 
fatty acids was analyzed in nonpolypoid colonic tissues of AOM-DSS treated mice 
using GC-MS. Mucosal EPA content significantly increased in the promotion and 
initiation groups compared to the control arm (p < 0.0001), indicating that 
supplemented EPA-FFA was efficiently incorporated in colonic tissues of mice treated 
with AOM-DSS (Figure 14). However, we didn't found differences of EPA 
incorporation between the promotion and initiation arms, although the latter started 
EPA-FFA diet 40 days before. 
 
Figure 14 Incorporation of dietary EPA-FFA in colonic tissues EPA colonic content was 
measured by GC-MS in AOM-DSS treated animals at the end of the end of the experimental 
protocol. Control group fed a Control diet and induced colon cancer by AOM and DSS (n = 13); 
Promotion and Initiation arms fed a diet containing 1% EPA-FFA and induced colon cancer by 
AOM and DSS  (n = 11 mice per group).  
Promotion and initiation arms showed significant increased percentage content of colonic EPA-
FFA as compared to the Ctrl arm.  
EPA levels were expressed as relative percentages of total fatty acids. Data are shown as 
means ± SEM. P < 0.05; ** P < 0.001; *** p < 0.0001; One-way ANOVA followed by 
Turkey’s for multiple comparison.  
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As regards the effects of EPA-FFA diets on total fatty acid composition, no variations 
were observed in the percentage content of palmitic and stearic acid among the three 
different groups. Otherwise, a lower percentage of oleic, linoleic and arachidonic acid 
was found in the colonic tissues of EPA-FFA treated mice respect to the Control group 
associated with a modest increase of  linolenic acid content. Importantly, we found that, 
compared to the Control group, in the colonic tissues of mice belonging to the 
promotion and initiation groups, EPA, DPA and DHA percentages, significantly 
increased in response to dietary EPA-FFA indicating the ability of the mice to 
efficiently incorporate EPA-FFA and to promote the conversion to DPA and DHA. The 
differences in fatty acids content between Control and EPA-FFA-supplemented groups 
were summarized in Table 4. 
 
Table 4 Effects of experimental diets on colonic fatty acids composition 
Fatty acids Control Promotion Initiation 
value of p             
(ANOVA) 
C16:0 (Palmitic) 26,29 ± 0,67 27,28 ± 1,22 25,60 ± 1,19 ns 
C18:0 (Stearic) 9,85± 1,74 14,50 ± 2,33 16,00 ± 2,37 ns 
C18:1 n-9 (oleic) 36,14  ± 2,13 28,08 ± 2,38 26,80 ± 2,23 0.0051 
C18:2 n-6 (linoleic) 17,97 ± 1,48 13,49 ± 1,61 13,68 ± 1,56 0.0419 
C20:4n-6 (arachidonic) 8,12 ± 1,77 5,62 ± 1,05 5,58 ± 0,78 0.0116 
C18:3 n-3 (linolenic) 0,37 ± 0,08 0,42 ± 0,07 0,54 ± 0,09 0.0071 
C20:6n-3 (docosahexaenoic) 0,90 ± 0,26 4,17 ± 0,64 4,29 ± 0,47 0.0371 
C22:5 n-3 (docosapentaenoic acid) 0,32 ± 0,06 2,76 ± 0,46 3,11± 0,46 0.0025 
C20:5n-3 (eicosapentaenoic acid) 0,01± 0,00 3,69 ± 0,28 4,46 ± 0,32 < 0.0001 
 
Data were expressed as percentage of fatty acid methyl esters ± SEM 
 
A higher ω-6/ω-3 PUFAs ratio is found in the western diet and resulted associated with 
a greater incidence of inflammatory related diseases including IBDs (Hou et al., 2011). 
Given the importance of an optimal ω-6/ω-3 ratio for health benefits, rather than the 
absolute percentage of individual PUFAs, we decide to focus our attention on the 
effects of EPA-FFA diet on the overall ω-6/ω-3 content. As shown in Figure 15, in 
EPA-FFA treated mice compared to the Control group, the combination of EPA, DPA 
and DHA, which represents ω-3 PUFAs, resulted significantly increased (P < 0.0001 for 
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each group vs. Control) (ANOVA P < 0.0001) at the expenses of the combined 
percentage content of mucosal ω-6 PUFAs arachidonic and linoleic acids which was 
significantly decreased in the same groups (P < 0.0001 for each group s. Control) 
(Figure 15). These results indicate that EPA-FFA dietary intake not only enriched the 
EPA content in the cellular membrane, but also increased the total (n-3) polyunsaturated 
fatty acid content reducing the ω-6/ ω-3 ratio. 
 
 
 
 
 
 
 
Figure 15  EPA-FFA modulates colonic fatty acids incorporation Colonic fatty acids 
composition was evaluated using GC-MS. A significant switch toward ω-3 PUFAs at the 
expenses of ω-6 PUFAs was observed in both promotion and initiation arms as compared to the 
Control group. Fatty acids levels were expressed as relative percentages of total fatty acids and 
analyzed using one-way ANOVA followed by Turkey’s for multiple comparison (Ctrl n = 13, 
Promotion and Initiation n = 11). * P ≤ 0.05; ** P ≤ 0.01; *** P≤  0.001 
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4.5 EPA-FFA incorporation reduces urinary PGE-M excretion 
To determine if changes in fatty acids composition associated with EPA-FFA 
consumption could be related to a modulation of PGE-2 production, we investigated the 
effect of EPA-FFA diet on PGE-2 biosynthesis in vivo by measuring urinary levels of 
its major metabolite PGE-M, by LC-MS/MS. We found that EPA-FFA dietary intake 
led to an important and statistically significant decrease of urinary levels of PGE-M in 
both promotion and initiation arms, indicating a lower systemic PGE-2 production 
respect to the Control arm. Interestingly, the percentage of PGE-M reduction appear to 
be dependent to the exposure time of the diet being of 20.5% in the promotion group 
and 50.1% in the initiation group (P < 0.001 initiation vs. Control; P < 0.05 promotion 
vs. Control) (ANOVA P = 0.009) (Figure 16).  
 
  
 
Figure 16  EPA-FFA reduces urinary PGE-M excretion. Pooled urinary samples deriving 
from each animal in a given treatment were analyzed using a LC-MS/MS system. EPA-FFA 
diet, compared to the Control group, resulted in decreased levels of PGE-M excretion in 
particular in the initiation arm. Data were expressed as nanogram PGE-M per mg creatinine and 
reported as means ± SEM. Analysis was performed using one-way ANOVA followed by 
Turkey’s for multiple comparison (Ctrl n = 13, Promotion and Initiation n = 11).  * P < 0.05; ** 
P < 0.001; *** P < 0.0001.  
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4.6 EPA-FFA reduced systemic but not colonic inflammation in AOM-DSS mouse 
model 
The exposition to the carcinogen AOM in combination with repeated DSS 
administrations led to a chronic inflammatory state in the colon and trigger a systemic 
inflammatory response, which contribute to promote colon tumorigenesis. For this 
reason, in this study, we investigated the influence of EPA-FFA dietary 
supplementation on systemic and colonic inflammation. Our results showed that the 
amount of pro-inflammatory cytokine IL-1β was significantly lower in the promotion 
group compared to the Control arm (P < 0.05 for promotion vs. Control). In addition, 
IFN-γ serum levels were lower in both EPA-FFA treated arms respect to the Control 
arm, while reaching statistical differences only in the initiation group (P < 0.0001 
initiation vs. Control). Otherwise, the content of all the other monitored cytokines (IL-6, 
IL-10, IL-17 and TNF-α) was comparable in all treated groups, suggesting that EPA-
FFA did not affect the circulating levels of these mediators (Figure 17). 
  
 
Figure 17  Effects of EPA-FFA diets on circulating cytokines levels Serum levels of 
indicated cytokines were measured with a multiplex bead-based sandwich immunoassay (Bio-
Plex) in AOM-DSS treated mice feeding the Control diet or EPA-FFA diet. Data were reported 
as means ± SEM. Analysis was performed using one-way ANOVA followed by Turkey’s for 
multiple comparison. Significant changes in circulating cytokines were observed for IL-1β 
(promotion) and IFN-γ (initiation). * P < 0.05, ** P < 0.001, *** P < 0.0001 vs. control. (Ctrl n 
= 13, Promotion and Initiation n = 11 
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In order to investigate the effect of EPA-FFA on colonic inflammation, colon lenght 
was used as macroscopically indication of colonic inflammation, while microscopic 
inflammatory alterations were estimated by using a histological scoring system. Despite 
the modest changes found on systemic inflammation, no significant differences were 
appreciated among the three different groups for colon lenght (Figure 18A) and colonic 
inflammatory score (Figure 18B). 
 
 
Figure 18 Effect of EPA-FFA on colon length and inflammatory score. Colon length was 
measured at the sacrifice. Inflammatory score was obtained using histological criteria indicated 
in the materials & methods. No differences were found in term of colon length (A) and 
inflammatory score (B) among the Control arm and EPA-FFA treated groups. Data were 
represented as mean ± SEM (Ctrl n = 13, Promotion and Initiation n = 11).  
 
The intestinal inflammation was also evaluated analyzing the gene expression profile of 
pro-inflammatory mediators in colonic tissues. We observed an induction of IFN-γ, IL-6 
and IL-1β mRNA levels in the AOM-DSS Control arm compared to the healthy mice, 
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while no differences were observed for TNF-α (Figure 17). However, according to the 
histological evaluation, we found no significant differences in the transcription levels of 
inflammatory mediators (IFN-γ, IL-6, IL-1β and TNF-α) among the Control group and 
EPA-FFA treated groups with an increasing trend in IFN-γ, IL-1β and TNF-α mRNA 
levels in the initiation group (Figure 19). These results indicate that while having a 
strong chemopreventive effect, the diets containing EPA-FFA had no effects on 
intestinal inflammation.  
 
 
 
 
Figure 19 Expression profile of colonic inflammatory cytokines Analysis by qRT-PCR of 
mRNA expression levels for indicated proinflammatory cytokines in colon from healthy mice 
and AOM-DSS treated mice fed with the Control diet or EPA-FFA diet. No significant changes 
were observed in the gene expression profile of proinflammatory cytokines IFN-γ, IL-1β, TNF-
α and IL-6 among the different arms. Data were normalized to GAPDH mRNA and expressed 
as means ± SEM (Healthy n = 8, Ctrl n = 13, Promotion and Initiation n = 11).   
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4.7 EPA-FFA induces Notch1 signaling activation in AOM-DSS mouse model 
Recent evidences support the hypothesis that deregulation of Notch signaling could play 
a crucial role in the evolution of CAC (Garg et al., 2011). In order to establish whether 
the chemopreventive effects of EPA-FFA in AOM-DSS mouse model could be 
connected to a modulation in Notch signaling pathway, and to establish whether EPA-
FFA treatment transcriptionally affect Notch signaling in this model, we measured  
changes in RNA levels of Notch1 downstream target genes Hes1, Nrarp and Atoh1. In 
addition, we  evaluate the expression profile of the Notch1 ligand Jagged1 in this 
context. Gene expression analysis revealed a suppression of  Notch signaling induced 
by AOM-DSS treatment compared to healthy mice as demonstrated  by a marked  
reduction of Hes1, Nrarp and Jagged1 and reciprocal increase of Atoh1 (Figure 20). 
Importantly, EPA-FFA treatment has proven to be able to counteract the Notch1 
repression caused by AOM-DSS exposition resulting in a significant upregulation of 
Nrarp in the initiation group (P < 0.001 for initiation vs. Control; P = n.s. for promotion 
vs. Control) (ANOVA P = 0.0032), an increasing trend for Jagged1 and a reciprocal 
decreasing trend for Atoh1. Moreover, despite the abolition of Hes1 expression 
observed  in the Control group respect to the healthy mice, EPA-FFA treatment was 
also associated with a modest increase of Hes1, in particular in the initiation arm.  
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Figure 20  EPA-FFA affect  Notch1 signaling pathway  mRNA expression levels of Notch1 
ligand Jagged 1 and downstream target genes of Notch signaling by q-RT-PCR in healthy mice 
and AOM-DSS treated mice fed with the Control diet or EPA-FFA diet. Compared to healthy 
mice, AOM-DSS treatment was associated to a downregulation of  (A) Jagged1, (B) Hes1 and 
(C) Nrarp with a reciprocal increase of Atoh1 (D). Of note, EPA-FFA counteract the effects 
induced by AOM-DSS. Data were normalized to GAPDH mRNA and expressed as means ± 
SEM (.Healthy n = 8, Ctrl n = 13, Promotion and Initiation n = 11).   
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4.8 EPA-FFA treatment modifies the gut microbiota composition in CAC  
Growing recent evidences suggest that the gut microbiota composition importantly 
contributes to the aetiology of CRC and CAC (Irrazábal et al., 2014). To test the 
hypothesis that EPA-FFA may exert its protective activity inducing specific changes in 
the microbial community structure associated with inflammation-driven CRC, we 
evaluated  the gut microbiota composition using stool samples from AOM-DSS treated 
mice feeding  the different diets. As a baseline control, we used the faecal samples taken 
from  healthy mice. We observed that while the microbiota structure was mainly 
represented by Bacteriodetes, which are typical of the mouse gut microbiota, the AOM-
DSS treatment  resulted to be associated to the appearance of Akkermansia sp., a mucin-
degrading species, belonging to the Verrucomicrobia phylum compared to the healthy 
mice (Figure 21). Importantly, EPA-FFA diet induced a significant enrichment of 
Lactobacillus sp. compared to the Control group (P = 0.003), which appeared to be 
more relevant in the promotion group. Interestingly, also a decreasing trend in 
Akkermansia population was noticed in both arms feeding EPA-FFA diet, while not 
reaching statistical differences. All data for each arm were reported in histograms  
describing the relative abundance of the microbial groups in each arm (Figure 21)  
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Figure 21   EPA-FFA induces changes in gut microbiota composition Composition of  
intestinal microbiota was evaluated by pooling faecal samples deriving from each animal in a 
given treatment using HTF. Microby Array. EPA-FFA led to significant increase of 
Lactobacillaceae (P = 0.003 Promotion and Initiation vs. Control). Data were reported as 
relative percentage of the indicated microbial groups in each arm (Healthy n = 8, Ctrl n = 13, 
Promotion and Initiation n = 11).    
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4.9 Expression of miR34-a in AOM-DSS treated mice and the influence of EPA-
FFA 
Due to the known tumor soppressor function of miR-34a  in CRC (Gao et al., 2014), we 
decided to explore the ability of EPA-FFA to exert its anti-cancer effects through a 
modulation of  miR-34a in our model. In this thesis we  evaluated the expression of this 
microRNA in normal colonic mucosa of AOM-DSS treated mice at the end of the 
experimental protocol. The results revealed an AOM-DSS-driven downregulation of 
miR-34a  in normal colonic mucosa of mice feeding the Control diet compared with 
healthy mice. Interestingly, as shown in Figure 22, EPA-FFA dietary supplementation 
resulted in a progressive induction of miR-34a expression,  in both arms treated with 
EPA-FFA. In particular, in the initiation group miR34-a levels reached values similar to 
the healthy group, while not reaching statistical significant differences.  
 
 
 
Figure 22   Influence of  EPA-FFA on miR34a expression qRT-PCR analysis of miR-34a on 
normal colonic mucosa of healthy mice and AOM-DSS treated mice fed with the Control diet or 
EPA-FFA diet. An upregulation of miR34a was observed in both arms fed with EPA-FFA diet 
compared to the Control group. No significant variations were observed among the 
experimental groups. Data were reported as relative percentage of the indicated microbial 
groups in each arm. (Healthy n = 8, Ctrl n = 13, Promotion and Initiation n = 11).    
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5. DISCUSSION 
The primary end point of this study was to investigate the potential chemopreventive 
effect of EPA-FFA on both initiation and promotion of CAC. We found that both 
feeding protocols containing EPA-FFA appeared equally efficient in counteracting the 
tumor incidence and multiplicity induced by the AOM-DSS treatment. Importantly, 
tumors size resulted significantly reduced in both arms fed with EPA-FFA diet 
compared to the Control group. Surprisingly, we didn’t find significant differences in 
terms of outcomes between the promotion and initiation protocols, although the latter 
was designed to start EPA-FFA diet 4 weeks prior to the AOM injection. We 
hypothesized that the lack of differences between the two experimental protocols could 
be due to the rapid incorporation and reaching a steady-state level by EPA-FFA. Indeed, 
the free-fatty acid formulation (FFA) doesn’t require the hydrolysis by pancreatic lipase 
and is therefore more efficiently absorbed and highly bioavailable. Supporting this 
hypothesis, no significant differences were observed in terms of ω-3 PUFAs 
incorporation between the promotion and initiation arms although, as compared to the 
control animals, they showed a significant increase. In addition, the possibility to use an 
FFA formulation allowed us to use a very low dosage of EPA in the diet (1%) 
approaching to a condition more suitable in humans. The impact of dietary fish oil (FO) 
in the context of a chemically-induced inflammatory-driven cancer model, was 
previously investigated only in another work performed by Monk et al which evaluated 
the effect of dietary ω-3 PUFAs in mice WT or harboring a deletion of PPARδ within 
the intestinal epithelium (PPARδΔIEpC) (Monk et al., 2012) . Interestingly, while 
conditional PPARδ knock-out appeared to have no effect on tumor incidence, they 
observed an exacerbation of colitis in PPARδΔIEpC mice and found a reduction of colon 
injury and tumor incidence in mice feeding a diet enriched in FO compared to the group 
consuming a Corn oil (CO) diet (Monk et al., 2012) . However, differently from our 
study, in which the genetic background of the animals is the same in all arms of 
treatment, they employed a more generic formulation of FO at a higher percentage in 
the diet (4% of FO vs. 1% EPA-FFA) and showed a protective effect only on CAC 
initiation. Importantly, our data show a strong chemopreventive effect of EPA-FFA not 
only in the initiation of CAC, but also in the promotion group which simulate the 
clinical scenario observed in patients with long-standing IBD. Different cellular and 
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molecular mechanisms have been suggested in order to explain the anti-cancer effects 
of ω-3 PUFAs including EPA, although most of them have emerged from in vitro 
studies and need to be further characterized and confirmed in vivo. One of the first 
proposed anti-cancer behaviour of EPA is linked to the ability of this natural compound 
to be incorporated into the cellular membranes and function as substrate for oxygenases 
such as COX-2 and cytochrome P450 mono-oxygenases. In particular, COX-2 
dependent synthesis of PGs in colorectal mucosa, especially through the PGE2 
production, represents a critical event in the pathogenesis of CRC (Hull et al., 2004). In 
this context, the interesting aspect of this potential EPA-driven mechanism is the 
capability to redirect the synthesis pathway of eicosanoids toward the production of 
anti-inflammatory and anti-tumorigenic PGE3 at the expenses of pro-inflammatory and 
protumorigenic PGE2 series, deriving from the arachidonic acid metabolism (Cockbain 
et al., 2012b). In this study, we found that EPA-FFA introduced with the diet was 
efficiently incorporated into the cellular membrane inducing important changes in the 
cellular fatty acids composition. Noteworthy, in both arms treated with EPA-FFA, we 
observed a significant increase of the overall ω-3 PUFAs content including EPA, DPA 
and DHA at the expenses of the percentage content of ω-6 PUFAs (arachidonic + 
linoleic acids). Interestingly, strengthening the previously mentioned hypothesis, this 
increased content of ω-3 PUFAs into the cellular membrane resulted associated with a 
decreasing trend of circulating levels of PGE2 in both arms feeding the EPA-FFA diet 
compared to the Control group, with a stronger effect evident in the initiation group. 
Immunohistochemical analysis of colon sections harvested from this study also revealed 
that EPA-FFA diet inhibited tumor growth slowing down the intestinal cell proliferation 
as highlighted by the reduced  reactivity of Ki-67 observed for both the promotion and 
initiation protocols at the same rate. In addition, there was also an increased number of 
TUNEL positive cells, a marker for apoptosis induction, in both EPA-FFA feeding arms 
with an higher rate of apoptotic cells detectable in the initiation group. It is also 
important to underlie that DHA exposure derived from fish oil increased colonocytes 
apoptosis in a study conducted by Ng Y et al. (Ng et al., 2005) and the chemopreventive 
properties of DHA against CRC were also extensively reported (Cockbain et al., 
2012b). In this study we observed an efficient conversion of dietary EPA-FFA to DHA 
and DPA in both arms feeding EPA-FFA. Given the higher overall content of ω-3 
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PUFAs found in the promotion and initiation arms compared to the Control group, the 
impact of EPA-FFA on apoptosis and cell proliferation could be enhanced through a 
synergistic effect of the combined ω-3 PUFAs. Importantly, in this work we found for 
the first time that EPA-FFA is able to modulate Notch1 signaling in vivo. Notch 
signaling has been recognized as a crucial molecular pathway for regulating self-
renewal of stem cell population in the normal intestinal mucosa, as well as for the 
determination of cell fate and terminal differentiation of proliferating cells (Guilmeau, 
2012). The canonical Notch signaling activation relies on the ability of a specific ligand 
(Jagged or DLL) to bind the extracellular portion of Notch receptors resulting in  the 
intramembrane receptor proteolysis sequentially mediated by ADAM and γ-secretase 
and subsequent cleavage and release of the Notch intracellular domain (NICD). This 
released active Notch fragment travels into the nucleus where, through the association 
with DNA binding protein CSL and the recruitment of the transcriptional coactivator 
Mastermind (MAM), assemble a transcription machinery that activates downstream 
target genes (Kopan and Ilagan, 2009). The critical involvement of Notch signaling in 
both CRC and CAC has been recently demonstrated in different studies (van Es et al., 
2005)(Garg et al., 2010). Interestingly, a complex interplay between Wnt and Notch 
signaling was reported in models of sporadic or FAP-related CRCs. In particular, the 
study conducted by Rodilla et al. described the Notch1 activation as a downstream 
event of Wnt signaling activation through beta-catenin-mediated transcriptional 
induction of the Notch-ligand Jagged1 and showed that deletion of one allele of Jagged1 
in mice Jag1
+/Δ
 crossed with APC 
Min/+ 
mice is sufficient to reduce the tumor size in 
APC mutant background indicating that activation of Notch1 by Jagged1 confers an 
advantage to β-catenin dependent tumors (Rodilla et al., 2009). Differently, in a later 
study performed by Kim et al. it was revealed a suppression of Wnt/ β-catenin target 
genes in Apc 
Min/+
 mouse model upon activation of Notch signaling. Importantly, this 
Notch-mediated negative effect on CRC development, appeared to be particularly 
evident during the promotion, rather than the initiation of CRC (Kim et al., 2012b). In 
this study, we observed a suppression of Notch1 activation in the normal colonic 
mucosa of AOM-DSS treated mice feeding the Control diet compared with healthy 
mice, as revealed by a marked downregulation of Jagged1, Nrarp and Hes1 mRNA 
levels, associated with a reciprocal increasing trend for Atoh1. Importantly, EPA-FFA 
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treatment was able to rescue the suppression of Notch1 activation induced by AOM-
DSS in both arms of treatment, but in particular in the initiation arm. Noteworthy, in the 
same experimental protocols a significant increase of apoptosis rate and a considerable 
reduction of tumor incidence was observed indicating that Notch1 works as a tumor 
suppressor in our model and more importantly Notch signaling constitutes a new in vivo 
target of EPA-FFA. Interestingly, in this study we also confirmed the existence of a 
negative correlation between the Notch1 activation and the β-catenin induction. Indeed, 
in AOM-DSS control arm, in which Notch1 signaling appeared to be off, we observed 
high levels of nuclear β-catenin as revealed by immunohistochemical analysis. 
Noteworthy, a significant reduction of nuclear β-catenin translocation was detected in 
both arms feeding EPA-FFA compared to the Control arm. Overall, our results were in 
line with a previous study by Garg et al. which proposed a tumor suppressor function of 
MMP-9 in CAC which occur directly modulating Notch activation leading to a 
concomitant suppression of β-catenin expression. The exact mechanism through which 
EPA-FFA can modulate Notch1 signaling is unknown. However, it has been 
demonstrated that ω-3 may exert anticancer effects inducing changes in lipid raft 
organization and function or altering caveolae lipid microenvironment (Yaqoob and 
Shaikh, 2010), (Ma et al., 2004). Importantly, caveolin-1, the principal component of 
caveolae, has been shown to critically modulate Notch1/NICD and Hes1 expressions in 
the brain regulating astroglial differentiation (Li et al., 2011). In addition, multiple 
mechanisms, including microRNAs, regulate Notch1 or Jagged 1 expression. For 
instance, miR-21 which resulted upregulated in AOM-DSS mouse model (Gao et al., 
2013), has been shown to repress Jagged1 (Hashimi et al., 2009). Interestingly, miR-21 
is targeted by ω-3 PUFAs in breast cancer cells (Mandal et al., 2012). The importance 
of alterations in gut microbiota structure in CRC occurring on inflammatory background 
was recently elucidated by Arthur et al in AOM-treated Il10
−/− 
mice which revealed the 
crucial role of bacterial species with genotoxic properties during CAC development 
(Arthur et al., 2012). They proposed a model in which inflammation promotes CAC 
onset and progression acting on both the host and the microbiota, leading to the 
expansion of microorganisms with genotoxic and mucin-degrading capabilities (Arthur 
et al., 2012). Of note, in this study we provide new evidences that support the 
implication of the gut microbiota composition in CAC development showing relevant 
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changes in the gut microbiota structure among healthy mice, AOM-DSS control and 
EPA-FFA fed mice. As expected, we found that the mouse intestinal microbiota of 
healthy animals which are fed with a control diet containing 1% of CO, is dominated by 
Bacteroides-Prevotella spp. from the Bacteroidetes phylum together with the specific 
populations of clostridial cluster XIVa. Noteworthy, in the AOM-DSS control group 
respect to the healthy mice we appreciated the appearance of Akkermansia sp., whose 
major representative A. muciniphila, a mucin-degrading species, resulted to be 4-fold 
higher in patients with CRC (Weir et al., 2013). In addition, according to our results, the 
increased abundance of  Akkermansia sp. was also found by Berry D. et al in DSS- 
treated mice which proposed the putative mucin degraders Akkermansia and 
Mucispirillum as indicator phylotypes for DSS treatment (Berry et al., 2012). These 
observations were supported  by the evidence that one of the features that marks the 
inflammatory bowel disease UC is the reduction of goblet cells and a progressive loss of 
mucus secretion (Kim and Ho, 2010). Strikingly, when AOM-DSS treated mice were 
fed with EPA-FFA diet, a decreased content of Akkermansia sp was progressively 
observed and more importantly, an enrichment of Lactobacillus sp. was found in both 
promotion and initiation arms compared with the AOM-DSS group fed with the control 
diet. The beneficial and protective properties of probiotic microorganisms against CRC 
development , including strains belonging to the Lactobacillus and Bifidobacterium 
genera, were reported in different studies (Khazaie et al., 2012), (Wollowski et al., 
2001). Moreover, Gosh et al recently showed that a dietary supplementation with ω-3 
PUFAs in a mouse model of infection-induced colitis, was able to induce the growth of 
beneficial bacterial strains such as Lactobacillus sp. and Bifidobacteria sp., as opposed 
to the effect induced by ω-6 PUFA rich diets (Ghosh et al., 2013). Our findings are in 
accordance with Gosh et al. suggesting that Lactobacillus sp., which is known to 
counteract the growth of potential pathogens, may have an important role in the 
protective effects of EPA-FFA in the context of CAC. Thus, we demonstrated that EPA-
FFA diet was able to ameliorate the intestinal dysbiosis induced by the DSS treatment, 
promoting the recovery of an healthy gut microbial ecosystem.  
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Several studies have shown important regulatory functions of miRNAs in different 
cancer-related biological processes including cell proliferation, apoptosis, invasion and 
metastasis (Lujambio and Lowe, 2012). Among the miRNAs with tumor suppressor 
functions, miR-34a is a typical one whose role was reported in different types of cancer, 
including both CRC and CAC (Gao et al., 2014), (Rokavec et al., 2014). Importantly, it 
has been recently reported that mice deficient for miR34-a (Mir34a–/–) are more 
susceptible to tumor development in AOM-DSS mouse model promoting tumor 
invasion (Rokavec et al., 2014). In our study, AOM-DSS treatment resulted in 
decreased expression of miR-34a in colonic mucosa of mice feeding the Control diet 
compared with healthy mice. Interestingly, EPA-FFA appeared to be able to reverse this 
phenomenon restoring miR-34a expression notably upon the initiation arm in which 
miR-34a levels reached values close to the healthy mice. Given the ability of EPA-FFA 
to induce miR-34a in AOM-DSS mouse model, we can speculate that this effect may 
represent a further chemopreventive mechanism mediated by EPA-FFA which need to 
be further investigated. Interestingly, in this study, despite the strong effect found in 
terms of chemoprevention of CAC, EPA-FFA treatment did not improve the colonic 
intestinal inflammation in mice treated AOM-DSS, although in the latter modest 
changes in systemic inflammation were found. Although the potential anti-
inflammatory properties of ω-3 PUFAs were highlighted in different studies, recent 
literature data suggested that a dietary supplementation with fish oil or other compounds 
performed during DSS-induced colitis could exacerbate the intestinal inflammation and 
increasing the mortality rate impairing the beneficial effects of these substances 
(Matsunaga et al., 2008), (Jia et al., 2011). Since these effects were mainly observed 
following an acute inflammatory insult induced by the DSS administration, we 
hypothesize that this effect may be due to the chemical interaction between 
chemopreventive substances and DSS. This assumption was sustained by the evidence 
that fat-1 transgenic mice, which can catalyze the endogenous conversion of ω-6 PUFA 
to ω-3 PUFA by introducing a double bond into fatty acyl chain, inducing an 
enrichment in endogenous ω-3 PUFAs, didn't show exacerbation of colitis during DSS 
treatment (Matsunaga et al., 2008). Thus, in our work in order to minimize the potential 
harmful effect of ω-3 PUFAs, we decided to withhold EPA-FFA feeding during DSS 
cycles by switching to Control diet. Importantly, we didn't find significant differences in 
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the mortality rates among the three different groups, while intensifying the 
inflammatory background which initiated and promoted the AOM-induced 
carcinogenesis performing three short DSS cycles (4 days) at a high concentration 
(2.5%). Of note, in order to simulate a dosage more suitable in humans, we used a 
purified formulation of EPA-FFA at a lower concentration (1%) compared with a 
previous study performed by our research group in Apc 
Min/+
 mouse model (Fini et al., 
2010). Therefore, we speculate that the controversial behavior of EPA-FFA in the 
resolution of inflammation, while having a strong effect on carcinogenesis, could be due 
to the use of a low dosage of EPA-FFA in a context of chemically-induced robust 
inflammation. Our findings were in accordance with previous evidences showing 
inconsistency between the levels of colonic inflammation and tumor development in 
CAC mouse models (Grivennikov et al., 2009),(Arthur et al., 2012). Concluding, we 
described new potential anticancer effects of EPA which appeared to be independent 
from the modulation of colonic inflammation in this system and importantly, we 
demonstrated that EPA-FFA is an effective chemopreventive agent in AOM-DSS 
mouse model. These evidences suggest that an  early EPA-FFA supplementation could 
represent a good strategy to prevent CRC development in patients with IBD.  
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